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THE STEM CELL HYPOTHESIS OF BREAST CANCER 
Breast cancer is one of the most common cancer in women (Edwards et al., 2005). There is 
increasing evidence that this cancer is originated in and maintained by a small population of 
undifferentiated cells with self-renewal properties (Reya et al., 2001). This small population 
generates a more differentiated pool of cells which represents the main mass of the tumor, 
resembling the hierarchical tissue organization of the normal breast. Adult normal stem cells have 
been isolated and studied in several tissues (Reya et al., 2001). In this regard, the existence of a 
reservoir of stem cells (see Figure 1), persisting throughout life and capable of multi-lineage 
differentiation is firmly established and well characterized for blood cells (i.e., RBCs, WBCs & 
platelets). Breast cancer almost always occurs in the luminal epithelial compartment, which is also 
where milk is produced. In 2002, Thorarinn Gudjonsson, successfully isolated cells from the human 
breast luminal compartment  with stem cell properties (Gudjonsson et al., 2002). In the normal 
mammary gland, cyclical changes of estrus and pregnancy, repeated though a lifetime, require the 
balanced maintenance of a diversity of cell types in response to a variety of external hormonal 
stimuli. This may render the mammary gland susceptible to the introduction of genetic errors that 
may accumulate in its stem cell population and ultimately lead to malignancy and metastasis. A key 
property of normal mammary stem cells is their extreme migratory responsiveness to cytokinetic 
and hormonal signals.  
Figure 1: A schematic picture 
showing the architecture of a mammary gland duct. The figure depicts the different position, within the duct, of stem 
cells, transit cells and differentiated epithelial cells (image taken from Nat Rev Cancer 3:832, 2004).
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Cancer stem cells seem to share a similar phenotype with their normal counterparts but they display 
dysfunctional patterns of proliferation and differentiation, and they no longer respond to normal 
physiological controls that ensure a balanced cellular turnover. The origin of these cancer stem cells 
is controversial; it is not well known if they are originated from normal stem cells or from more 
differentiated progenitors where a de novo stem cell program is activated by the oncogenic insult 
(see Figure 2).  
 
 
 
 
 
Figure 2: Breast cancer stem cells may originate from normal stem/progenitor stem cell (A) or bipotential stem cell (B) 
and can give raise to breast cancers over-expressing peculiar lineage markers (i.e. luminal, basal-like, epidermal growth 
factor 2 positive, HER2+, or epidermal growth factor 2 negative, HER2-) (image taken form Polyak, 2007 Cancer 
Cell).
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MAMMARY CANCER STEM CELLS:EXPERIMENTAL EVIDENCES 
It has been recently proposed that a population of aberrant stem-like cells within a breast tumor is 
critically involved in the initiation of cancer disease. The tumor engraftment capacity (the ability to 
establish tumors in immune deficient mice mammary fat pads) of breast cancer cells is almost 
restricted to a sub-population of CD44 expressing cells, that have been consequently called tumor 
initiating cells or breast cancer stem cells (Al-Hajj et al., 2003, Ponti et al., 2005; see Figure 3). 
Human breast cancer stem cells can be propagated in vitro as multicellular spheroids, named 
mammospheres (MS) (Dontu, 2008; Farnie et al., 2007; see Figure 4). MS derived from breast 
tumor tissues and from breast cancer cell lines over-express the cancer stem cell marker CD44 and 
are extremely enriched in tumorigenic cells that show enhanced resistance to cancer therapy-
induced cell death (Ponti et al., 2005; Kuperwasser, 2008). In vivo, the breast cancer stem cell 
phenotype is over-expressed in breast cancer bone marrow micro-metastasis and in aggressive 
inflammatory and basal-like breast carcinoma subtypes (Balic et al., 2006; Xiao et al., 2008). 
Understanding the biology of the tumor-initiating cell population in breast cancer would have a 
profound impact on how we design therapies, particularly those targeting cells with metastatic 
potential. It would also greatly enhance our ability to predict the metastatic potential of individual 
tumors and help patients and their physicians to select the most promising treatment options.  
                              
Figure 3: This picture shows that the tumorigenic potential of breast cancer cells in nude mice is restricted to CD24low 
breast cancer cells (picture taken from Al-Hajj et al., 2003 PNAS).  
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Figure 4: Stem/progenitor cells can be isolated from fresh breast tissue and grown in vitro in non adherent cellular 
condition as multicellular spheroids (mammaspheres) which can differentiate when plated in plastic or matrigel coated 
wells and promote breast tumorigenesis when injected and serially transplanted in nude mice. 
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IL-6: IN VITRO STUDIES IN BREAST CANCER 
Cytokines are pleiotropic molecules who share common characteristics:  
a) they are biologically active at low concentrations (pg/ml-ng/ml);  
b) they exert their biological effects by binding and signaling through cell surface receptors; 
c) they can be additive, synergistic, or antagonistic (Knupfer et al., 2006).  
Interleukin-6 (IL-6) is a 30 kilodalton (kDa) cytokine discovered in 1986 and is known mainly for 
its role in mediating an immune response through expansion and activation of T cells and 
differentiation of B cells (Heinrich et al., 2003; see Figure 5). In addition, it is a central molecule 
in acute and chronic inflammatory settings (Gabay et al., 2006). While IL-6 has been studied 
extensively in chronic inflammatory diseases its role in breast cancer progression is less clear 
(Knupfer et al., 2006). IL-6 used in vitro both inhibited growth (Asgeirsson et al., 1998) and 
promoted growth (Honma et al., 2002; Miki et al., 1989) of breast cancer cell lines. IL-6 has been 
shown to augment survival of breast cancer cells through increases in pro-survival proteins such as 
BCL-2, BCL-xL, and MCL-1 (Brocke-Heidrich et al., 2006; Leu et al., 2003). Moreover, IL-6 
production has been linked to increased drug resistance in breast tumor cells. Conze, et al showed 
that MCF-7 breast carcinoma cells became resistant to chemotherapeutic agents when stably 
transfected with IL-6 (Conze et al., 2001). Haverty et al showed that breast carcinoma cells that 
produced autocrine IL-6 had increased heat shock protein GP96, which promoted a drug resistant 
phenotype (Haverty et al., 1997). IL-6 has also been shown to increase breast cancer cell motility 
in vitro through decreased cell adhesions, which might contribute to cell metastasis (Asgeirsson et 
al., 1998; Tamm  et al., 1989,1994a,b). Additionally, IL-6 induced during hypoxia upregulates 
VEGF through a specific response element upstream of the VEGF transcription start site to promote 
angiogenesis (Bachelot et al., 2003). This response could be extremely important in tumor 
progression when considering the implications of angiogenesis on tumor growth and metastasis. 
Overall, these observations in breast cancer are supported by an extensive body of literature 
documenting the ability of IL-6 to promote growth, survival, and drug resistance in multiple 
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myeloma, hepatocellular carcinoma, prostate carcinoma, and renal cell carcinoma cells (Cavarretta 
et al., 2006; Hsia et al., 2006; Wallner et al., 2006).  
 
 
 
Figure 5: IL-6 production and role in the immune response. 
 
IL-6 AND BREAST CANCER IN VIVO 
While the in vitro data on IL-6 in breast cancer is conflicting, the clinical literature depicts a much 
clearer picture of the biological impact that IL-6 has on disease progression. IL-6 has been shown to 
be an independent prognostic indicator of breast cancer progression (Zhang and Adachi, 1999). In 
addition, multiple clinical studies have demonstrated increased patient serum levels of IL-6 
correlate with more aggressive disease. Two independent groups demonstrated increased IL-6 
serum levels were associated with advanced breast cancer staging (Knupfer et al., 2006; 
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Jablonska et al., 2001). Salgado et al showed increased serum IL-6 levels correlated with the 
number of metastatic sites in the patient (Salgado et al., 2003). Furthermore, Zhang, et al. showed 
that serum IL-6 is inversely correlated with patient response to treatment (Zhang and Adachi, 
1999). Patients with complete response to therapy had average serum IL-6 of 2.4 pg/ml (+/-1.2), 
partial responders were 4.1 pg/ml (+/- 1.0), non-progressive patients were 7.4 pg/ml (+/- 2.8), 
progressive disease patients were 36.3 pg/ml (+/- 13.2) (Zhang and Adachi, 1999). These studies 
demonstrate that elevation in IL-6 levels correlates with a poor prognosis in metastatic breast 
cancer. In fact, Bachelot, et al. looked at both VEGF and IL-6 levels in relation to survival in breast 
cancer patients. VEGF serum levels had no correlation to survival times. However, high IL-6 serum 
levels indicated a poor prognosis. Patient serum levels of IL-6 below 13 pg/ml demonstrated a 
median survival time of 13 months, while levels above 13 pg/ml had only 4 months. Patients with 
levels above 55 pg/ml had a median survival time of only 1 month, versus a median 3 years survival 
for patients below 55 pg/ml (Bachelot et al., 2003). In vitro data supporting the role of IL-6 in the 
promotion of breast cancer remains confounding and the mechanism behind these clinical 
observations remains unknown. 
IL-6 PRODUTION AND SIGNALING 
IL-6 is mainly produced by adipocytes, immune cells, and vascular endothelial cells (Heinrich et 
al., 2003). When signaling, it binds first to its 80 kD extramembrane alpha receptor (IL-6Rα or 
CD126) and then induces homodimerization of its 130 kD transmembrane signaling receptor 
(GP130). When bound by the IL-6/IL-6R complex, GP130 activates Janus kinases (Jak) and 
downstream signal transducer and activator of transcription (STATs), also known as the Jak/STAT 
pathway. STATs 1, 3, and 5 are the main mediators of IL-6 signaling (see Figure 6). These 
transcription factors are maintained in the cytoplasm until phosphorylated, at which time they 
dimerize, translocate to the nucleus, and induce gene expression (Heinrich et al., 2003). GP130 can 
also activate the MAPK cascade through the adaptor protein SH2-and collagen-homology-domain-
containing-protein (Shc). In addition, the PI3K cascade can also be activated by IL-6. These 
signaling cascades can induce many biological changes within the affected cell.  
 
Figure 6: The IL6/Stat3 signaling 
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Signal transducers and activators of transcription (STATs) are a family of transcription factors that 
integrate cytokine and growth factor signaling to alter gene expression required for cell growth, 
survival, differentiation, and motility (Haura et al., 2005; Bromberg et al., 1999). Two members 
of the family, STAT3 and STAT5 are increasingly associated with the progression of breast 
carcinoma (Clevenger, 2004). STAT3 exists in the cytoplasm of a cell in a latent form until 
activated by cytokine (IL-6, LIF, oncostatin, IFN, etc) or growth factor signaling. When a cytokine 
or growth factor binds to its receptor dimerization occurs and induces a signaling cascade that 
quickly activates Janus kinases (Jaks) through autophosphorylation (Clevenger, 2004). Once 
phosphorylated, Jaks recruit STAT3 to dock at the receptor/Jak complex. Jak proteins then induce 
tyrosine phosphorylation of STAT3 that promotes STAT3 to dissociate from the receptor complex, 
dimerize, and translocate into the nucleus (see Figure 6). Once in the nuclear compartment, STAT3 
binds to gene promoters through a DNA specific recognition sequence, recruits co-activator or co-
repressors, and affects gene transcription (Levy and Lee, 2002).  
The first link to STAT3 and oncogenesis was the 1990s discovery that v-Src transformed cells had 
constitutively activated STAT3 (Yu et al., 1995). In addition, it was shown that a constitutively 
active mutant STAT3 was able to transform fibroblasts and allow them to form tumors in mice, 
establishing the role of STAT3 as an oncoprotein (Bromberg et al., 1999). Since these studies, 
activated STAT3 has been linked to multiple malignancies, including breast cancer. Multiple 
studies have shown via immunohistochemistry that activated STAT3 (nuclear STAT3) is increased 
in malignant tissue compared to normal controls (Dolled-Filhart et al., 2003). Evidence from in 
vitro findings supports these results. Many studies have demonstrated a tumor promoting role for 
activated STAT3 in cancer cell lines (Grandis et al., 1998). Several inhibitors of the STAT3 
pathway have been tested in vitro and in vivo and show proof of concept by increased tumor cell 
death and decreased in vivo malignancy (Selander et al., 2004). These drugs are still in early 
development and it remains to be seen how they will fair in a clinical setting. 
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NOTCH SIGNALLING IN BREAST CANCER 
Notch genes, encode highly conserved cell surface receptors (Kidd et al., 1986). The Notch 
signaling pathway, in which almost all elements are conserved from Drosophila to humans, consists 
of Notch receptors, ligands, negative and positive modifiers, and transcription factors (Kidd et al., 
1986). In mammals, these functional classes each have multiple members, and the interplay 
between these molecules is not yet fully understood. Studies in Drosophila suggest, however, that 
Notch receptors and ligands generally influence lineage specification through two mechanisms: 
lateral inhibition and lateral induction (Welshons et al., 1962). In contrast, inductive signaling 
involves two non-equivalent cell types that express either the receptor or the ligand. The receptor 
expressing cell responds to ligand stimulation, triggering a cell fate decision dependent on access to 
the appropriate ligand(s). During the development of complex tissues, both mechanisms may be 
operative. 
.  
Figure 7: (a) Pictorial representation of a Notch protein and its signalling pathways. The extracellular domain of Notch 
contains between 29 and 36 tandemly repeated epidermal growth factor (EGF)-like repeats, some of which are required 
for the interaction of Notch with its ligands, along with three Lin-12/Notch repeats. The most prominent motifs in the 
intracellular domain are six cdc10/ankyrin repeats and a PEST domain close to the C-terminus of the protein. The 
intracellular domain also contains two functionally defined domains: the juxtamembrane RAM23 domain that mediates 
the interaction of the intracellular domain of Notch with CBF1, Suppressor of Hairless, Lag-1 (CSL) proteins; and a 
transcriptional activation domain that is C-terminal to the cdc10/ankyrin repeats. (b) The interaction of Delta, Serrate, 
Lag-2 (DSL) ligands (black) with EGF-like repeats 11 and 12 of Notch (dark blue and yellow) leads to two proteolytic 
cleavages, one extracellularly and one within the membrane, which release the intracellular domain of Notch (NICD). 
This fragment of Notch then migrates to the nucleus (dotted line) where it interacts with CSL proteins (orange) via its 
RAM23 domain to form a transcriptional activator. (c) Recent experiments have suggested that Notch can signal 
through a second distinct signalling pathway that requires the cytoplasmic protein Deltex (light blue). Deltex has been 
shown to interact directly with the cdc10/ankyrin repeats of Notch, and signalling through this pathway has been 
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proposed to both inhibit Jun N-terminal kinase (JNK) signalling and to sequester the transcriptional coactivator CREB 
binding protein (CBP)/p300 (picture taken from Brennan et al., Breast Cancer Res 2003).  
 
An interesting aspect of Notch is its double function as a tumor suppressor and oncogene. Although 
the mechanism underlying this dual Notch action is being explored, the outcome of Notch signaling 
activity depends on signal strength, timing, cell type, and context (Maillard and Pear, 2003). The 
result of altered Notch signaling depends on its normal function in a given tissue. Notch thus acts as 
an oncogene if its normal function is as a gatekeeper of stem cells or as a regulator of precursor cell 
fate; its tumor suppressor activity is detected in tissues in which Notch signaling initiates terminal 
differentiation events (Radtke and Raj, 2003). Notch alone may not be a very efficient oncogene, 
however, and it must associate with another oncoprotein to cause transformation. Although such 
partners have not yet been identified in naturally occurring tumors, transformation can be induced 
in vitro in various cell types by expressing NICD with certain oncoproteins (Girard et al., 1996; 
Beverly et al., 2003). Mouse Mammary Tumor Virus (MMTV) is a retrovirus that causes mammary 
tumors through insertional mutagenesis of the mouse genome. Notch4 was identified as a mouse 
mammary tumor virus (MMTV) insertion site in mammary tumors (Nusse, 1988); provirus was 
inserted within the Notch4 gene (originally known as the int-3 locus) (Smith et al., 1995). This 
MMTV model system has proven useful for identification and characterization of genes involved in 
malignant transformation of normal mammary epithelium (Nusse, 1988). In the case of the Notch4 
gene, provirus insertion leads to expression of a truncated Notch that lacks most of the extracellular 
portion of the protein but contains Notch4 transmembrane and intracellular domains (N4ICD) 
(Gallahan and Callahan, 1997). Transgenic mice harboring this constitutively active N4ICD under 
the regulation of the MMTV promoter show arrested mammary gland development and eventually 
develop poorly differentiated adenocarcinomas (Smith et al., 1995). Additional evidence confirms 
the Notch4/int-3 gene effect in mammary epithelial differentiation and mammary tumorigenesis; 
this is derived from studies in which N4ICD was expressed from the whey acidic protein (WAP) 
promoter in transgenic mice, which restricts its activity to secretory mammary epithelial cells of 
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pregnant mice (Gallahan et al., 1996). As predicted, secretory lobule growth and differentiation 
were inhibited, and mammary tumors were histologically identical to MMTV-N4ICD tumors. 
Enforced expression of int-3/Notch4 in cultured mammary epithelial cells induces anchorage-
independent growth, matrix invasion and loss of contact inhibition (Dievart et al., 1999). Notch1 
involvement in mammary tumorigenesis is being studied extensively. The first evidence that 
aberrant Notch1 signaling has a role in mammary tumorigenesis came from studies in the MMTV 
model, which attempted to identify genes that collaborate with Neu/erbB2 in mammary 
tumorigenesis. An MMTV insertion in the Notch1 locus in MMTV-Neu mammary tumors causes 
N1ICD expression (Dievart et al., 1999). HC11 mouse mammary epithelial cells expressing 
N1ICD-encoding cDNA are transformed, form colonies in agar, but are unable to form tumors in 
nude mice, indicating that acquisition of malignant characteristics requires additional genetic events 
(Dievart et al., 1999). Other studies showed that transgenic activation of N1ICD in mammary 
glands leads to development of lactation-dependent tumors that regress at weaning (Kiaris et al., 
2004; , Hu et al., 2006); with time, these regressing neoplasms apparently become non-regressing 
adenocarcinomas (Kiaris et al., 2004). Stem cells thought to reside in the mammary gland are 
thought to renew mammary gland cells through cycles of pregnancy, lactation, and involution 
during a woman’s lifetime (Woodward et al., 2005). There is increasing evidence that stem cells 
might be targets of transformation during mammary carcinogenesis (Woodward et al., 2005). The 
Notch signaling pathway is implicated in the self-renewal of normal mammary stem cells (Dontu et 
al., 2003, 2004), and recent works suggest a role for the Notch pathway in breast cancer (Liu et al., 
2005; Yamaguchi et al., 2008).  
Information on Notch in human breast cancer is scarce and indirect. Notch1-4 mRNA/proteins are 
expressed in selected human breast cancer cell lines and tumors (Stylianou et al., 2006). In tissue 
samples from breast cancer patients, Parr et al. (Parr et al., 2004) quantified NOTCH1 and 
NOTCH2 expression in association with clinical outcome and showed aberrant NOTCH1 and 
NOTCH2 levels in breast cancer tissues compared with normal breast tissue. Examination of the 
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clinicopathological parameters for breast cancer patients indicated that high NOTCH1 levels may 
be associated with poor prognosis, whereas increased NOTCH2 levels correlated with greater 
probability of survival (Parr et al., 2004). NOTCH1 may thus have tumor-promoting functions, 
whereas NOTCH2 could have a tumor-suppressive role in human breast cancer, supporting the 
suppression of NOTCH-1 activity as a therapeutic strategy. Tissue microarray studies showed high 
JAGGED1 and/or NOTCH1 expression levels in human breast cancer, associated with poor overall 
survival compared with patients with low levels of these genes (Reedijk et al., 2005). 
Because high-level JAGGED1 and NOTCH1 co-expression showed a synergistic effect on overall 
survival, this type of breast tumor could also benefit from notch inhibition-based therapy. 
Other studies on NUMB expression (the inhibitor of notch signaling) in human breast cancer also 
supports NOTCH signaling pathway involvement in breast cancer. (Pece et el., 2004; Colaluca et 
al., 2008) showed that NUMB-mediated negative regulation of NOTCH signaling is lost in 50% of 
human mammary carcinomas. This is due to specific NUMB ubiquitination and proteasomal 
degradation (Pece et el., 2004) and indicates that enhanced NOTCH signaling activity occurs in 
these mammary carcinomas. Overall, all these molecular and phenotypic evidences demonstrated a 
pivotal role for Notch in the breast cell fate determination and tumorigenesis. 
 
CHAPTER 1 
ABSTRACT 
High serum levels of Interleukin-6 (IL-6) correlate with poor outcome in breast cancer patients. 
However no data are available on the relationship between IL-6 and stem/progenitor cells which 
may fuel the genesis of breast cancer in vivo. Herein, we address this issue in mammospheres (MS), 
multi-cellular structures enriched in stem/progenitor cells of the mammary gland, and also in MCF-
7 breast cancer cells. We show that MS from node invasive breast carcinoma tissues express IL-6 
mRNA at higher levels than MS from matched non-neoplastic mammary glands. We find that IL-6 
mRNA is detectable only in basal-like breast carcinoma tissues, an aggressive variant showing stem 
cell features. Our results reveal that IL-6 triggers a Notch-3-dependent up-regulation of the Notch 
ligand Jagged-1, whose interaction with Notch-3 promotes the growth of MS and MCF-7 derived 
spheroids. Moreover, IL-6 induces a Notch-3-dependent up-regulation of the carbonic anhydrase IX 
gene, which promotes a hypoxia-resistant/invasive phenotype in MCF-7 cells and MS. Finally, an 
autocrine IL-6 loop relies upon Notch-3 activity to sustain the aggressive features of MCF-7-
derived hypoxia-selected cells. In conclusion, our data support the hypothesis that IL-6 induces 
malignant features in Notch-3 expressing, stem/progenitor cells from human ductal breast 
carcinoma and normal mammary gland.  
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                                                        LIST OF ABBREVIATIONS 
IL-6 Interleukin-6  
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INTRODUCTION AND HYPOTHESIS 
 
Interleukin 6 (IL-6), a major mediator of the inflammatory response, plays a primary role in 
the patho-physiology of cancer (Hodge et al., 2005; Rose-John et al., 2006). In breast cancer 
patients, the extent of the increase in serum IL-6 correlates with a poor disease outcome and a 
reduced prognosis (Knupfer and Preiss, 2007;  Bachelot et al., 2003). Though it has been argued 
that the cytokine may be secreted by cancer cells, the source of the IL-6 in cancer patients has not 
yet been determined (Zhang and Adachi, 1999; Knupfer et al., 2004). Cancer cells exposed to IL-
6 or which secrete the cytokine as an autocrine factor, show malignant features, such as an 
enhanced capacity to invade the extracellular matrix and an increased drug resistance (Conze et al., 
2001; Sehgal et al., 2001). Accordingly, the inactivation of the gp130 protein, which transduces the 
signalling of IL-6 type cytokines, has been found to reduce the aggressiveness of breast cancer cells 
in vivo (Selander et al., 2004). On the basis of these data, the inhibition of the IL-6/IL-6 receptor 
interaction with specific antibodies has been proposed as a support cancer therapy (Trikha et al., 
2003). 
Breast cancer has been proposed as a stem cell disease (Dontu et al., 2005). This hypothesis 
entails the notion that the growth of the tumour mass relies on the proliferation and self renewal 
capacity of a small population of cancer-initiating cells, also named cancer stem cells (Dontu et al., 
2005). Moreover, this notion helps to understand why the dys-regulation of stem cell regulatory 
pathways plays a causative role in breast cancer (Reya et al., 2001). In this regard, transgenic mice 
over-expressing isoforms of Notch, a signalling pathway active in stem cells, are more prone to 
develop mammary tumours (Hu et al., 2006). Further, high levels of Notch isoforms have been 
found to correlate with a poorer prognostic profile and reduced survival in breast cancer patients 
(Reedijk et al., 2005; Stylianou et al., 2006). The molecular profile analysis of breast cancer stem 
tumorigenic cells revealed an up-regulation of IL-6 and of Notch-3, a stem cell regulatory gene 
(Shipitsin et al., 2007). 
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Stem/progenitor cells of the mammary gland reside in the basal cell layer (Boecker et al., 
2003) and can be expanded in vitro from normal tissues as multi-cellular spheroids, named 
mammospheres (MS) (Dontu et al., 2003). Prior findings indicate that multi-cellular MS structures 
have a clonal origin and have the capacity to reform in vitro after trypsin dissociation. (Dontu et al., 
2003). Bi-lineage (luminal and myo-epithelial) progenitors are enriched up to eight times in MS, 
compared to freshly isolated human mammary cells, and constitute virtually 100% of the cells in 
secondary MS (Dontu et al., 2003, 2005). MS regenerate and also form tubulo-alveolar structures 
in matrigel and in immunodeficient mice cleared of fat pads (Dontu et al., 2003, 2004, 2005; 
Farnie et al., 2007). Similarly, MS from breast cancer tissues have been shown to proliferate in 
vitro and also generate tubulo-alveolar structures composed of CD44+/CD24- cells (Farnie et al., 
2007; Ponti et al., 2005). Interestingly, the CD44+/CD24- positive cell population has been shown 
to be extremely enriched in putative breast cancer stem cells (Al-Hajj et al., 2003).  
Both normal and tumor MS have been shown to require  active Notch signalling to sustain 
their survival and proliferation capacity (Dontu et al., 2004). Moreover, MS express gp130 and are 
potential targets of IL-6 type cytokines (Dontu et al., 2003).  
In this thesis we provide evidence that IL-6 gene expression is up-regulated in MS obtained from 
aggressive ductal breast carcinomas and that IL-6 regulates a Notch-3-dependent signalling pathway 
that  promotes self renewal and the invasive potentials of normal and tumour MS. 
There is evidence that hypoxia affects stem cell function and survival (Cejudo-Martin et al., 2005; 
Covello et al., 2006; Ramirez-Bergeron et al., 2001). In vitro, hypoxia actively maintains a stem 
cell/immature phenotype, induces a loss of differentiation markers, and blocks differentiation 
(Cipolleschi et al., 1993; Gustafsson et al., 2005). In vivo, stem cells express higher levels of 
hypoxia regulated genes than the more mature progeny, as well as high levels of glycolytic enzymes 
(Unwin RD et al., 2006). Accordingly, stem cells reside in tissue regions (the niche) that are scarce 
in vasculature and are thought to provide a low oxygen environment (Nilsson et al., 2001). 
Furthermore, stem cells are enriched up to 1000 folds among a pool of cells (the so called side 
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population), which expresses high levels of the hypoxia-survival gene Bcrp-I (Krishnamurthy et 
al., 2004). Recent data indicate that the stem cell regulatory Notch pathway shares in an interplay 
with the hypoxia response modulator HIF-1 to promote the onset of a stem/undifferentiated 
phenotype (Gustafsson et al., 2005). These findings, linking stem cells with hypoxia survival, lead 
to hypothesise that the control of stem cell survival and the regulation of hypoxia response are 
intimately coupled, and that they may share common control gene/pathways. In this thesis, we also 
provide evidence that IL-6 induced by the exposure to hypoxic stimuli, controls the expression of 
the stem cells regulatory gene Notch-3. Then, we report that a IL-6/Notch-3 interplay elicits an 
ERK-dependent up-regulation of at least two genes: the Notch ligand Jagged-1, and the hypoxia 
survival gene Carbonic Anhydrase IX. Finally, we convey that IL-6/Notch-3/CA-IX axis sustains 
mammosphere survival in presence of hypoxia. We propose that the findings here reported may 
help in understanding the relationship among inflammation, hypoxia survival, cancer and stem cells 
at molecular level. 
 
 
 
 
 
 
 
 
 
  
 
 
MATERIALS AND METHODS 
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Chemicals and reagents. 
 Monoclonal Antibody (MoAb) which blocks the activation of Notch-3 protein, by inhibiting 
the Notch-3/Jagged-1 interaction was purchased from R&D. MoAb which blocks the IL-6 
receptor/ligand interaction (anti-IL6) and recombinant human Interleukin-6 were purchased from 
Sigma. Desferoxamine (DFX, Sigma) was used as hypoxia mimetic, UO-126 (Sigma) was used as 
MEK1 inhibitor. 
 
Generation of mammospheres (MS) from normal and ductal breast carcinoma tissue specimens 
(CHAPTER 1). 
 Seventeen fresh surgical specimens obtained from patients with ductal breast carcinoma, who 
underwent to quadrantectomy or mastectomy, were collected to generate mammospheres, MS 
(Table 1). Normal and tumor samples were hystologically characterized (as reported below) to 
ensure the proper classification of normal and tumor tissue. Particular care was paid to generate MS 
from specimens in which only normal or tumor tissues were detectable at hystological examination. 
The set of samples consisted in a subset of tumor specimens (n=3), in which also the mRNA of the 
tumor tissues from which the MS had been originated was available, and of a subset of specimens 
(n=14), in which even the normal tissue from the same patient was available (Table 1). MS were 
obtained as previously described (Dontu et al., 2003; Farnie et al., 2007), except that the 
methodology was downscaled to deal with low amounts of tissues 300 to 900mg. Briefly, tissues 
were placed in sterile Epicult (StemCell Technologies), minced with sterile scalpels and incubated 
for 6 to 12 hours in presence of 1000 Units of Collagenase/Hyaluronidase enzyme mix (StemCell 
Technologies). Samples were centrifuged at 80Xg for 2 minutes, the pellet was digested by Dispase 
and DNAse for 3 minutes (StemCell Technologies), and then pelletted at 450Xg for 5 minutes. 
Pellets were re-suspended, filtered through a 40M nylon mesh (Becton Dickinson), and plated into 
1 or 3 cm2 wells low attachment plates (Corning), filled with 3 ml of Mammary Epithelial Growth 
Medium (MEGM), supplemented with B27 supplement, EGF 10ng/ml, bFGF 10ng/ml, 10g/ml 
 26
Insulin, Hydrocortison 10-6M, and ad hoc aliquots Gentamycin and Amphotericine (Cambrex). 
Primary MS started forming after 4 to 6 days, and were processed at day 10. Experimental 
procedures (see below) were performed on secondary MS, generated by incubating primary MS in 
1X Trypsin-EDTA solution (Cambrex) for 3 minutes, followed by two washes in complete MEGM 
and a filtration troughout a 40m nylon mesh. Self renewal of MS was tested by assessing the 
capacity of primary MS to generated secondary MS after trypsin disaggregation, as previously 
described (Dontu et al., 2003, 2004). Secondary MS were assessed at day 7. All the procedures 
were approved by the local ethical committee and by the patient’s written informed consent. 
 
Clinical samples and primary cell culture (CHAPTER 2). 
43 fresh surgical specimens from patients with ductal breast carcinoma who underwent 
quadrantectomy were processed to obtain MS as previously described (Table 3). All procedures had 
been approved by the local ethical committee (protocol number 56/2006/U/Tess to M.B.) and by the 
patient’s written informed consent. 
 
In vivo tumorigenicity. 
Cell invasion assay was performed on breast cancer cells (3*104) and trypsin dis-aggregated MS 
and MCF-7(S) (5*102 cells), as previously described. Six females BALB/c nude mice were injected 
with 5*105 MCF-7 cells. Mice were followed up for 3 months, prior of being sacrificed. Three 
tumor xenografts were formalin-fixed, paraffin-embedded for immunohistochemical analysis, or 
immediately frozen in liquid N2 for RT-PCR analysis. All procedures had been approved by the 
local ethical committee (protocol number 06-18-09-05).  
 
 27
Immunohistochemistry. 
 Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tumor samples 
(Table 1-4) and on N-/T-MS (embedded in collagen (Sigma) 2h before fixation in formalin). 
Tissues were histologically classified according to WHO criteria and graded (G) following Elston 
and Ellis’ classification (Tavassoli et al., 2003; Elston et al., 1991). The tumours were also typed 
by nuclear grading (NG) as follows: mild (NG1), moderate (NG2) and severe (NG3) nuclear atypia. 
Tumour size (pT) and axillary lymphnode involvement (pN) were also recorded using pTNM 
(UICC) pathological staging criteria (Elston et al., 1991). Serial sections of formalin-fixed paraffin-
embedded samples were de-waxed, re-hydrated, and subjected to antigen retrieval treatment. Tumor 
sections were stained using monoclonal antibodies anti-estrogen receptor (ER, clone 1D5), 
cytokeratin-5 (CK-5 clone D5/16B4) and Epidermal Growth Factor Receptor (EGF-R, clone 
DAHK1-WT) obtained from DakoCytomation (Glostrup), ErbB-2 (HER-2, clone CB11) and 
cytokeratin-14 (CK-14, clone LL002) from BioGenex Laboratories and CA-IX (M-75), kindly 
provided by Dr J. Pastorek (Slovak Academy of Sciences, Bratislava, Slovak Republic). Sections of 
normal and tumor MS were stained with anti CK-5, CK-14, EGF-R, CK-18 (CK-18, clone KSB17, 
Sigma), Oct-4 (clone c-20, Santa Cruz), CD44 and CD24 (Clone 156-3C11 and Clone 24C02, 
Neomarkers), CD133 (Miltenyi Biotec), and E-Cadherin (clone NCH38, DakoCytomation). 
Antigens were unmasked with Tris-EDTA pH 9.0 at 98°C for 20 min, except for CA-IX antibody. 
Endogenous peroxidase activity was inhibited using a 0.5% H2O2 solution in methanol for 20 min, 
and sections were processed for immunohistochemistry with a non-biotin amplified method 
(Novolink, Novocastra Laboratories). Stained immunoreaction was quantified by image cytometry 
using Cytometrica software (C&V, Bologna, Italy). Sections were independently evaluated by two 
pathologists, and controversial results were discussed and defined. For ER immunostaining, the 
percentage of the labeled nuclear area over the total neoplastic nuclear area was assessed (<10% 
nuclei= negative, >10% nuclei=positive). A semi-quantitative assessment was applied for CK-5, 
CK-14 and EGF-R evaluation: cases were considered positive when the immunopositive neoplastic 
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population was > 10%. HER-2 staining was scored according to the HercepTest United States Food 
and Drug Administration-approved grading system. The percentage of immunopositive cells in 
normal and tumor MS was assessed on three to five sections (accounting from 100 to 300 cells as 
average). 
 
Cell cultures. 
 MCF-7 cells were grown in RPMI 1640 medium 10%FBS (Euroclone). Hypoxia (<0.1%O2) 
was generated in 95%N2, 5%CO2 incubator (Thermo). MCF-7 derived multi-cellular spheroids, 
MCF-7(S) were generated by re-suspending 1x104 MCF-7 cells in complete RPMI 1640 medium 
and plated in 3cm2 low attachment plates (Corning). Hypoxia-resistant MCF-7 derived cells, 
HYPO-7 cells, have been previously described (Sansone et al., 2007). 
 
Hypoxia induced cell death. 
 Cell death was induced by exposing MCF-7 cells, Hypo-7 and MS to DFX at a concentration 
of 100, 600 and 50M, respectively, following previously described protocols (Sansone et al., 
2007). Cell death in MS was evaluated by Trypan blue staining of single cells obtained from the 
trypsin disaggregation of MS. 
 
Transient and stable RNA interference.  
Double strand RNA oligonucleotides (siRNA) directed against IL-6 (StealthTM validated 
RNAi DuoPaks), CA-IX and Jagged-1 (StealthTM select 3 RNAi set) mRNA, and appropriate 
controls, scramble (SCR) siRNAs were purchased from Invitrogen (Carlsbad). siRNAs were 
transfected to adherent MCF-7 cells (105 cells in a 3 cm2 well) at a concentration of 1g/well, using 
Lipofectamine 2000 (Invitrogen). siRNA transfection in MS and MCF-7(S) was performed by 
mixing 1g of siRNA with In vitro JET-PEI reagent (Poly plus Trasfection). Notch-3 specific short 
hairpin RNA (shRNA) was obtained by cloning an oligonucleotide consisting of a BglII site, a 21-
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22-nt sense sequence (GATCCCCCT CCCCTCACCACCTAA TAAAT / TCAAGAGATTTATTA 
GGTGG TGAGGG GAGTTTTTG GAAC), a short spacer (TTCAAGAGA), a 21-22-nt antisense 
sequence (TCGAGTTCC AAAAA CTC CCC TCA CCACCT AATAAA TCT CT TGAAT TTAT 
TAGGTGG TGAGGGGAGGGG), five thymidines (a stop signal for RNA polymerase III) and a 
XhoI site, into the pSuper-Puro expression retroviral vector (OligoEngine). The same vector 
encoding for a shRNA which does not match to any human known transcript (5' gatcccc AATATC 
CTTGGA CACAAG TTG ttcaagaga CAACTT GTGT CCAA GGATATT tttttggaac 3') was used as 
control (CT) for N3 shRNA. Retroviral gene transfer was performed as follows: Phoenix cells 
(gently provided by Dr. Gary Nolan, Stanford University, California, USA) were grown at 60% 
confluence and were transfected overnight with 30µg of the pSuper-Puro vector encoding a 
N3/CTR shRNA, using Lipofectamine 2000 (Invitrogen). Two days after transfection, the medium 
containing newly packaged retrovirus was collected and filtered through a 0.45µm pore size filter. 
After supplementation with 4µg/ml polybrene (Sigma), the augmented medium was applied to 
MCF-7 cells at 50% confluence for 24 hours. Successfully infected cells were selected by culturing 
the cells in presence of 2µg/ml Puromycin for 2 weeks.  
 
Expression vectors.  
The active form of Notch-3 (pNICD-3) was cloned by PCR, using the following primers: F-
TCTTGCTGCTGGTCATTCTC; R-GGCCCCCAAGATCTAAGAAC, using Herculase Taq 
polymerase (Stratagene). The PCR product was inserted into pcDNA3.1/V5-His Topo TA 
Expression Vector (Invitrogen).  
 
RT-PCR analysis. 
 Total RNA was extracted from cultured cells, MS, and from archival tissues (n=19, Table 1, 
samples 1-3 and Table 2) which had been frozen in liquid nitrogen at the time of surgical resection, 
using the RNA-extracting reagent TRIzol® (Invitrogen). Primers used in the RT-PCRs are: IL-6: 
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annealing temp 62°C, amplicon length 170 bp, F-5’-GAGAAAGGAGAC ATGTAACAAGAGT-
3’, R-5’-GCGCAGAATGAGATGAGTTGT-3’; Notch-3: annealing temp 62°C, amplicon length 
93 bp, F-5’-TCAGGCTCTCACCCTTGG-3’, R-5’-AGTCACTGGCACGGTTGTAG-3’; CA-IX: 
annealing temp 61°C, amplicon length 589 bp, F-5- CAGGGACAAAGAAGGGGATGAC-3’, R-
5’-TTGGAAGTAGCGGCTGAAGTCA-3’; Bmi-1, annealing temp 62°C, amplicon length 220 bp, 
F-5’GGAGACCAGCAAGTATTGTCCTTTTG-3’, R-5’-CATTGCTGGGCATCGTAAG-3’; 
Jagged-1: annealing temp 62°C, amplicon length 170 bp, F-5’-TCGCTGTATCTGTCCACCTG-3’, 
R-5’-AGTCACTGGCACGGTTGTAG-3’; CK-5: annealing temp 55°C, amplicon length 409bp, F-
5’ TAGGTGGTGGGCTCAGTGTGG-3’, R-5’-ACTTTGGGTTCTCGTGTCAGC-3’; CD133: 
annealing temp 60°C, amplicon length 286bp, F-5’- CTGGGGCTGCTGTTTATTATTCTG-3’, R-
5’- ACGCCTTGTCCTTGGTAGTGTTG -3’; BCRP-I: annealing temp 62°C, amplicon length 
400bp, F-5’ GTTTATCCGTGGTGTGTCTGG -3’, R-5’- CTGAGCTATAGAGGCCTGGG -3’; 
CD44: annealing temp 62°C, amplicon length 300bp, F-5’ CAGCAACCCTACTGATGATGACG-
3’, R-5’- GCCAAGAGGGATGCCAAGATGA -3; Oct-4: annealing temp 62°C, amplicon length 
169bp, F-5’ CTTGCTGCAGAAGTGGGTGGAGGAA -3’, R-5’- 
TGCCCGAAACCCACACTGCAG -3; Beta2 microglobulin: annealing temp 58°C, amplicon 
length 180, bp F-5’-ACCCCCACTGAAAAAGATGA-3’; R-5’-ATCTTCAAACCTCCATGA-3’. 
PCR primers and reagents were purchased from Invitrogen. 
 
Boyden Chamber Invasion assay. 
Cell invasion into Matrigel was assessed by using Boyden chambers (New Technologies 
Group), containing a poly-vinyl-pyrrolidone free polycarbonate filters with 8-μm pores, coated with 
15μg of Matrigel (Sigma). Cells (1 x 105) and trypsin dis-aggregated MS (1-5 x 102cells) were 
seeded in the upper chamber in serum-free medium, in presence/absence of IL-6 (10ng/ml) or anti-
IL6 (1.5g/ml); complete medium was placed in the lower compartment as chemoattractant. In 
several experiments cells and MS were also transfected with appropriate siRNA for 48h and then 
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were collected, re-suspended in 500l in co-presence of IL-6 (10ng/ml) or anti-IL6 (1.5g/ml) and 
seeded in the upper chamber for 24 h at 37° C in a 5% CO2 atmosphere. At the end of incubation, 
non invading cells were removed from the upper surface of the filters, and invading cells in the 
lower surface were fixed in ice cold methanol, stained with Toluidine Blue staining (Sigma) and 
scored as the mean number of invaded cells per 5 random optical fields, in three independent 
experiments, at a 20X magnification. 
 
Gelatin zymography.  
Metalloproteinase-2 (MMP-2) activity was determined by gelatin zymography. Briefly, 
proteins of collected media were precipitated with 1:4 (vol/vol) ice-cold methanol overnight at -
20°C, solubilized with sample buffer without mercaptoethanol (1 M Tris-HCl, pH 6.8, 2% SDS, 
10% glycerol) and loaded into 10% SDS-polyacrylamide gel containing 1 mg/mL gelatine (Sigma). 
Gel was then incubated in a developing buffer (100 mM Tris-HCl, 10 mM CaCl2, 20 mM NaCl, pH 
7.6) overnight at 37°C, stained for 2h with 1% Coomassie Brilliant Blue R-250, and finally de-
stained in a solution containing 10% acetic acid and 40% methanol. MMP-2 proteolytic activity was 
quantified using a semiautomated image analysis (GelDoc, Biorad Laboratories)  
Western Blot. 
 Cell lysates were prepared, run and blotted using standard methodologies, and probed specific 
antibodies: Rabbit polyclonal anti-Notch-3 (clone M-134, Santa Cruz), Mouse monoclonal 
Antibodies anti-ERK and phosphorylated ERK (Cell Signalling), -Actin (Sigma) and CA-IX 
(clone M-75). 
 
Statistical analysis. 
 Continuous variables (percentages of dead cells, number of invading cells in Boyden Chamber 
assays) were analysed by Anova (unequal variance assumed). Post hoc test (unequal variance 
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assumed) were used when comparison were > 2. Non-normally distributed variables (RT-PCR 
normalized values of mRNA level) were analyzed by two samples non parametric test (Mann 
Whitney). Categorical variables (MS and spheroid size distribution) were analyzed by Monte Carlo 
2 test. All the tests were implemented in SPSS 10.1 Package (SPSS). 
 
 
 
 
 
 
 
 
 
 
RESULTS 
High levels of Interleukin 6 (IL-6) mRNA are present in mammospheres (MS) from aggressive 
ductal breast carcinoma and in basal-like breast carcinoma tissues. 
MS were generated from the tumor tissues (T-MS) of 3 patients  with  ductal breast 
carcinoma (Table 1, samples 1-3 and Figure 1A).  
T-MS were characterized by immunohistochemistry (IHC). We found that T-MS were 
composed almost entirely by CD44+ (97±3%), CD24-(<1%) cells (Supplementary Figure 1), 
suggesting that the majority of cells in T-MS present a CD44+/CD24- cancer stem cell phenotype 
(Al-Hajj et al., 2003). Further, cells in T-MS expressed Oct-4 (88±7%), which has been previously 
reported to be hyper-expressed in T-MS (Ponti et al., 2005), and Cytokeratine 5 (CK-5, 22±7%), 
which identifies the mammary gland basal cell compartment (Boecker and Buerger, 2003; 
Supplementary Figure 1). IHC showed also that T-MS were composed by E-Cadherin positive 
(97±2%), CK-14 positive (99±1%) and CK-18 positive (24±7%) cells, revealing that T-MS are 
composed of epithelial cells showing ductal (CK-18) and luminal (CK-14) markers (Supplementary 
Figure 2). 
RT-PCR analysis revealed that T-MS, but not the tumour tissues which T-MS had been 
obtained from, expressed detectable level of IL-6 mRNA (Figure 1B). Compared to tumour tissues, 
RT-PCR analysis also revealed that T-MS expressed high levels of Bmi-1 mRNA, a gene associated 
with stem cell renewal (Liu et al., 2006), of CD44 mRNA, a gene whose expression has been 
associated with cancer stem cell phenotype in different organs (Al-Hajj et al., 2003; Li et al., 
2007), as well as of CK-5 and Oct-4 mRNA (Figure 1B). 
T-MS were then obtained from a set of samples (n=14), in which also the normal mammary 
gland tissue was available to generate normal MS (N-MS), (Table 1, samples 4-17). 
Similarly to T-MS, N-MS lacked CD24 expression and contained cells expressing CD44 
(95±3%), CK-5 (14±3%), CK-14 (78±7) and CK-18 (75±9, Supplementary Figure 3). The 
availability of N-MS and T-MS from the same patient allowed us to assess the level of IL-6 mRNA, 
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taking into account for variability due to the genetic make-up and age (Bonafe et al., 2001). We 
found that, compared to matched N-MS, T-MS from node invasive tumours (pN3/pN2) expressed 
increased levels of IL-6 mRNA (Figure 1C). The same comparison performed on T-MS generated 
from scarcely node invasive tumours (pN0/pN1) ductal carcinomas revealed a negligible difference 
in IL-6 mRNA level between N- and T- MS (Figure 1C). Notably, compared to matched N-MS, T-
MS obtained from patients affected by pN3/pN2 invasive tumours expressed similar levels of Bmi-
1 and CK-5 mRNA, lower levels of Breast cancer resistance protein 1 (BCRP-I) mRNA, as well as 
of CD133 mRNA, two antigens which have been previously associated with (cancer) stem cell 
phenotype (Singh et al., 2004; O'Brien et al., 2007; Ho et al., 2007; Figure 1C). The higher level 
of CD133 expression in N-MS compared to T-MS was also evident in IHC analysis (Supplementary 
Figure 4A). 
We then assessed IL-6 mRNA in a set of archival breast tumour samples (Table 2), 
including ductal (n=10) and basal-like (n=6) breast carcinomas, a subtype of cancer showing stem 
cell features (Nielsen  et al., 2004; Bertheau  et al., 2007; Bertucci  et al., 2007; Charafe-
Jauffret et al., 2006). This tumour type, similarly to MS, was characterized by the expression of 
CK-5, CK-14, Epidermal Growth Factor Receptor (EGF-R) protein, as well as of Bmi-1 and CD133 
mRNA (Supplementary Figure 4B and C) thereby reinforcing the notion of a tight similarity 
between MS and basal-like breast carcinoma cells (Charafe-Jauffret et al., 2006). 
In keeping with this reasoning, we found that IL-6 mRNA was detectable in basal-like breast 
carcinoma tissues, but not in ductal breast carcinoma (Figure 1D). These data indicate that IL-6 
expression occurs in MS obtained from aggressive ductal breast carcinoma and in basal-like breast 
carcinoma tissues, wherein stem cell-like phenotypes are particularly apparent. 
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FIGURE 1A, Phase contrast microscopy analysis of day 10 primary tumor (T-) mammospheres 
(MS) generated from samples listed in Table 1, Scale bar=100m.  
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FIGURE 1B, RT-PCR analysis of IL-6, Bmi-1, Cytokeratin 5 (CK-5), CD44, Oct-4, 2 mRNA 
level in T-MS and in tumor tissues which T-MS had been obtained from.  
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FIGURE 1C. Interleukin-6 (IL-6) mRNA is expressed in mammospheres and in basal-like 
breast carcinoma tissues Day 10 primary normal (N-) and T-MS obtained from the same patient 
(Table 1): RT-PCR analysis of IL-6, Bmi-1, CK-5, BCRP-1 and CD133 and bar graph 
representation of IL-6, Bmi-1 and CK-5 mRNA level, first normalized onto 2 mRNA, and then 
expressed as a ratio of N-MS over T-MS, Mann-Whitney (MW) test, *p=0.031, NA: not available, 
NS: not significant.  
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FIGURE 1D, Breast carcinoma tissues from patients affected by basal-like or ductal breast 
carcinoma (Table 2): Bar graph representation of RT-PCR analysis of IL-6 ratio over 2mRNA 
level (#p=0.001, MW test).  
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 IL-6 promotes MS self-renewal and MCF-7 derived spheroids MCF-7(S) formation. 
To assess the functional role of IL-6 expression in MS, we exposed secondary T-MS to a 
monoclonal antibody which blocks the IL-6 receptor/ligand interaction (anti-IL6, 1.5g/ml). 
Exposure of T-MS to anti-IL6 antibody substantially blunted their secondary regeneration capacity, 
a functional property which has been referred to MS self-renewal capability (Dontu et al., 2003, 
2004;  Figure 2A). Accordingly, we observed that, the administration of IL6 (10ng/ml) to N- and T-
MS from the same patient yielded an increase in secondary MS formation, compared to MS not 
exposed to the cytokine, a phenomenon which was hampered by the simultaneous addition of anti-
IL-6 (1.5g/ml, Figure 2B). We further investigated this phenomenon in the context of MCF-7-
derived spheroids MCF-7(S), which have been recently shown to contain a substantial proportion of 
CD44+/CD24- cells (Phillips et al., 2006). MCF-7(S) expressed high levels of IL-6 mRNA, 
whereas the mRNA of the cytokine was absent in MCF-7 cells cultured in standard conditions 
(Figure 2C). Moreover, the administration of anti-IL6 (1.5g/ml) caused a substantial reduction in 
MCF-7(S) size (Figure 2C). These data indicate that IL-6 mRNA expression promotes growth in 
suspension, and that both autocrine and exogenous IL-6 promotes MS self-renewal. 
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FIGURE 2. IL-6 sustains MS self renewal and MCF-7 spheroid formation. 
A, Day 7 Secondary T-MS, generated from primary T-MS in presence/absence of a MoAb which 
blocks the IL-6 receptor/ligand interaction anti-IL6 (1.5g/ml): phase contrast microscopy analysis 
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and number of MS per well (n=3, *p=0.029; **p=0.042, Anova test); B, phase contrast microscopy 
analysis and number of MS per well in day 7 secondary T- and N-MS generated from primary MS 
in presence/absence of IL-6 (10ng/ml) and anti-IL6 (1.5g/ml), respectively: (n=3, §p=0.027, 
§§p=0.020, #p=0.048; ##p=0.035, Anova test, Post Hoc tests adjusted for multiple comparisons); C, 
RT-PCR analysis of IL-6 mRNA level in MCF-7 and Day 2 MCF-7 derived spheroids and MCF-
7(S) generated in presence/absence of anti-IL6 (1.5g/ml): phase contrast microscopy analysis and 
MCF-7(S) size distribution. N= refers to the number of spheroids counted for each sample (°p=0.02, 
Monte Carlo2 test). 2 was assessed as quantitative control for RT-PCR analysis. Scale 
bar=100m. 
The MCF-7(S) growth promoting activity of IL-6 requires Notch-3 gene. 
Notch genes play a pivotal role in MS self-renewal (Dontu et al., 2004; Farnie et al., 2007). 
In particular, Notch-3 is highly expressed in N-MS (Dontu et al., 2003), and its blockage induces a 
marked reduction in MS self-renewal and survival (Supplementary Figure 5). On these basis, we 
tested the hypothesis that the effect of IL-6 on MS self-renewal and MCF-7(S) formation may 
depend upon the Notch-3 gene expression. We found that the administration of anti-IL6 (1.5g/ml) 
to T-MS for 24h yielded a down-regulation in the level of Notch-3 mRNA, as well as that the 
administration of IL-6 (10ng/ml) to N-MS for 24h elicited an up-regulation of Notch-3 mRNA 
(Figure 3A). A similar regulation was observed in MCF-7 cells and MCF-7/(S) exposed to IL-6 
(10ng/ml, 24h), and in MCF-7(S) exposed to anti-IL6 (1.5g/ml, 24h, Figure 3B). To better 
characterize the role of IL-6/Notch-3 interplay in substrate-independent growth, we generated 
MCF-7(S) using MCF-7 cells stably transduced with a retroviral vector expressing  a Notch-3 
specific (shN3/MCF-7) or control (shCT/MCF-7) shRNA. We found that MCF-7(S) obtained from 
shCT/MCF-7 cells and generated in the presence of IL-6 (10ng/ml) showed an increase in size, 
whereas shN3/MCF-7 cells did not produce MCF-7(S), even in presence of exogenous IL-6  
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(10ng/ml, Figure 3C). These data indicate that Notch-3 signalling is of pivotal importance to sustain 
the IL-6 dependent growth of breast cancer cells in suspension culture. 
  FIGURE 3. IL-6 induces the Notch-3 gene up-regulation and the Notch-3-dependent MCF-
7(S) formation. A, RT-PCR analysis of Notch-3 mRNA level in day 10 primary N-MS in 
presence/absence of IL-6 (10ng/ml) and in T-MS in presence/absence of anti-IL6 (1.5g/ml) for 
24h; B, RT-PCR analysis of Notch-3 mRNA level in MCF-7 cells cultured in presence/absence of 
IL-6 (10ng/ml), and in MCF-7(S) in presence/absence of anti-IL6 (1.5g/ml) or IL-6 (10ng/ml) for 
24h; C, Day 7 MCF-7(S) generated from MCF-7 cells infected with a pSuperPuro retroviral vector 
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encoding a Notch-3-specific (shN3) or control (shCT) shRNA, in presence/absence of IL-6 
(10ng/ml): phase contrast microscopy analysis and MCF-7(S) size distribution (N= refers to the 
number of spheroids counted for each sample, *p=0.034; NS=Not significant, Monte Carlo 2test); 
WB analysis of Notch-3 and -Actin protein level. 2 was assessed as quantitative control for RT-
PCR analysis. Scale bar=100m. 
IL-6 elicits a Notch-3 dependent up-regulation of Jagged-1 mRNA expression which sustains MCF-
7(S) formation and promotes MS self-renewal. 
We found that Notch-3 promotes MS survival and that it regulates the expression of its 
ligand Jagged-1 (Supplementary Figure 5-6). Therefore we next evaluated if Jagged-1 was involved 
in Notch-3 dependent MS growth. Indeed either exposing N-MS to IL-6 (10ng/ml) or adding anti-
IL-6 (1.5g/ml) to T-MS modulated the expression of Jagged-1 mRNA (Figure 4A). Moreover, we 
found that in MCF-7 cells, IL-6 elicited an up-regulation of Jagged-1 mRNA, which was blocked 
by the co-administration of IL-6 with the MEK/ERK inhibitor UO-126 (Figure 4B). Furthermore, 
we found that the up-regulation of Jagged-1, induced by IL-6 was negligible in shN3/MCF-7 cells, 
and that the transfection of a plasmid encoding the activated form of Notch-3 (pNICD3) into MCF-
7 cells triggered an up-regulation of Jagged-1 mRNA, which was prevented by the concurrent 
administration of UO-126 (Figure 4B). In addition, we observed that MCF-7(S) formation was 
extremely reduced when MCF-7 were transfected with a Jagged-1 specific siRNA (JAG1), 
compared to scrambled (SCR) control siRNA (Figure 4C). Finally, we observed that an antibody 
blocking Jagged-1/Notch-3 interaction reduced MS regeneration capacity (see Figure 4D), 
indicating that the Notch-3/Jagged-1 pathway is functionally relevant for IL-6 induced MS 
formation. Notably, we also found that basal like breast carcinoma tissues expressed higher Jagged-
1 and Notch-3 mRNA levels than ductal breast carcinoma tissues (Figure 4E). These data suggest 
that up-regulation of Jagged-1 via Notch-3 signalling is crucial for the growth in suspension of 
breast cancer cells and MS, and that this phenomenon may also occur in basal-like breast cancer 
tissues. 
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FIGURE 4. Notch-3/Jagged-1 interplay sustains MCF-7(S) formation and MS self-renewal. 
A, Day 10 primary N-MS and T-MS cultured in presence/absence of IL-6 (10ng/ml) or anti-IL6 
(1.5g/ml) for 24h: RT-PCR analysis of Jagged-1 mRNA level; B, RT-PCR analysis of Jagged-1 
mRNA level, and WB analysis of phosphorylated ERK and total ERK protein level in MCF-7 cells 
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exposed to IL-6 (10ng/ml) in presence/absence of the MEK1 inhibitor UO-126 (20M) or DMSO 
for 24h, in shN3/shCT MCF-7 cells exposed to IL-6 (10ng/ml, 24h), and in MCF-7 cells transfected 
with 1g pCDNA3.1 vector encoding Notch-3 intracellular active cleaved fragment (pNICD3), or 
empty control vector (pEMPTY) for 24h, in presence/ absence of UO-126 (20M) or DMSO; C 
Day 7 MCF-7(S) generated from MCF-7 cells transfected with Jagged-1 specific or SCR siRNA 
(1g, 72h of pre-exposure): RT-PCR analysis of Jagged-1 mRNA level, phase contrast microscopy 
analysis, MCF-7(S) size distribution, (#p=0.001, Monte Carlo 2test); D, Day 7 secondary N-MS 
generated in presence of IL-6 (10ng/ml) and in presence/absence of a MoAb which blocks Notch-3 
activity (anti-N3, 1.5g/ml): phase contrast microscopy analysis, N-MS size distribution (N= refers 
to the number of spheroids counted for each sample, Monte Carlo 2 test, §p=0.039, **p=0.009, Post 
Hoc tests adjusted for multiple comparisons, NS=not significant); E, Bar graph representation of 
RT-PCR analysis of Jagged-1 and Notch-3 mRNA level (ratio over 2mRNA) in basal-likeor 
ductal carcinoma tissues (##p=0.005, §§p=0.042, MW test). 2 was assessed as quantitative control 
for RT-PCR analysis. -Actin was assessed as quantitative controls for WB analysis. Scale 
bar=100m. 
IL-6 induces a Notch-3 dependent up-regulation of carbonic anhydrase IX (CA-IX) gene. 
ERK up-regulation has recently been found to enhance the expression of the hypoxia 
survival gene carbonic anhydrase IX (CA-IX, Kopacek et al., 2005). Thus given our above 
observations, we next evaluated whether IL-6 signalling modulates CA-IX gene expression. Indeed 
adding IL-6 (10ng/ml) to N-MS induced an up-regulation of CA-IX mRNA (Figure 5A). Increased 
CA-IX expression was also observed in MCF-7 cells exposed to IL-6 (10ng/ml, 24h), whereas CA-
IX gene expression was markedly reduced by the administration of UO-126 (Figure 5B). Similarly 
to what we observed for Jagged-1 (see Figure 4B), CA-IX gene expression was inhibited in 
shN3/MCF-7, but not shCT/MCF-7 cells exposed to IL-6, while it was enhanced by transfection of 
the pNICD3 vector but not in the presence of UO-126 (Figure 5B). Because CA-IX is a hypoxia 
response gene (Kopacek et al., 2005), we investigated whether IL-6 plays a role in the hypoxia 
response. Exposure of MCF-7 cells to hypoxic stimuli (100M Desferroxamine, DFX, or low 
oxygen tension, <0.1%O2, 48h), as well as the exposure of N- and T- MS to 50M DFX (48h), 
enhanced the expressions of IL-6, Notch-3 and CA-IX mRNAs (Figure 5C). Importantly upon 
blocking the up-regulation of hypoxia responsive genes with 100M DFX, the administration of 
anti-IL6 (1.5g/ml) to MCF-7 cells caused a down-regulation of Notch-3 and CA-IX mRNA. In 
addition, CA-IX mRNA was also down-regulated in shN3/MCF-7 cells exposed to 100M DFX 
compared to shCT/MCF-7 cells (Figure 5D). Taken together these results indicate the CA-IX gene 
expression is regulated by IL-6/Notch-3 pathway in MCF-7 cells and MS. 
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FIGURE 5. The IL-6/Notch-3 cross-talk promotes the up-regulation of carbonic-anhydrase IX 
(CA-IX) gene. 
A, Day 10 primary N-MS cultured in presence/absence of IL-6 (10ng/ml) for 24h: RT-PCR analysis 
of CA-IX mRNA level; B, RT-PCR analysis of CA-IX mRNA level and WB analysis of CA-IX 
(phosphorylated ERK, total ERK and -Actin protein level are reported in Figure 4B) in MCF-7 
cells exposed to IL-6 (10ng/ml, 24h) in presence/absence of UO-126 (20M) or DMSO, in 
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shN3/shCT MCF-7 cells exposed to IL-6 (10ng/ml, 24h), and in MCF-7 cells transiently transfected 
with pNICD3/pEMPTY vector (1g), co-administered with UO-126 (20M) or DMSO for 24h; C, 
RT-PCR analysis of IL-6, Notch-3, CA-IX mRNA level in MCF-7 cells exposed to low oxygen 
level (<0.1%O2) or 100M Desferoxamine (DFX), and in N-/T-MS exposed to 50M DFX for 48h; 
D, RT-PCR analysis of Notch-3 and CA-IX mRNA level in MCF-7 cells in presence/absence of 
anti-IL6 (1.5g/ml), and in shN3/shCT-infected MCF-7 cells exposed to DFX (100M, 24h), WB 
analysis of Notch-3 and.-Actin protein level2 was assessed as quantitative control for RT-PCR 
analysis. 
 
IL-6/Notch-3/CA-IX axis promotes hypoxia survival in MCF-7 and MS. 
CA-IX gene has been found to play a crucial role in hypoxia survival of MS (Supplementary 
Figure 7). In keeping with these data, we observed a substantial increase in cell death of MCF-7 
cells exposed to 100M DFX in the presence of anti-IL-6 (1.5g/ml), or transfected with a CA-IX-
specific siRNA, compared to matched controls (Figure 6A). Further, a higher degree of hypoxia-
induced cell death, accompanied by a down-regulation of CA-IX mRNA was observed in 
shN3/MCF-7 cells, compared to shCT/MCF-7 cells (Figure 6A). In line with these results, we found 
that the exposure of T-MS to anti-IL-6 or anti-N3 (1.5 and 1g/ml, respectively), or the transfection 
with CA-IX siRNA, in the presence of 50M DFX, increased in cell death  in comparison to a 
matched SCR siRNA control (Figure 6B). Interestingly, detectable levels of CA-IX mRNA were 
found only in tissues from basal like breast carcinoma (Figure 6C). These data indicate that IL-
6/Notch-3 induced CA-IX gene expression promotes hypoxia survival in MS, and support the 
similarity between the gene expression profiles of MS and basal-like breast carcinoma tissues. 
 
  
 
FIGURE  6. The IL-6/Notch-3/CA-IX axis promotes hypoxia survival. 
A, MCF-7 cells in presence/absence of DFX (100M, 48h): presence/absence of anti-IL6 
(1.5g/ml, 24h), transient transfection with  the CA-IX specific or SCR siRNA (1g, 72 hours), and 
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shN3/shCT MCF-7 cells (WB analysis of Notch-3 and -Actin protein level): cell death analysis 
and RT-PCR analysis of Notch-3 and CA-IX mRNA, n=3, *p=0.017, **p=0.008, ***p=0.002, 
anova test); B, cell death analysis and RT-PCR analysis of Notch-3 and CA-IX mRNA level in day 
7 secondary T-MS exposed to 50M DFX for 48h, in presence/absence of anti-IL6 (1.5g/ml, 48h) 
or anti-N3 (1.5g/ml, 48h), or transfected with CA-IX/SCR siRNA (1g, 72 hours, n=3, #p=0.022, 
##p=0.025, ###p=0.044, anova test); C, Breast carcinoma tissues from patients affected by basal-like 
or ductal breast carcinoma (Table 2): RT-PCR analysis reported as bar graph representation of CA-
IX/2mRNA ratio (§p=0.002, MW test), and a representative immunohistochemical analysis of 
CA-IX protein expression2 was assessed as quantitative control for RT-PCR analysis. Scale 
bar=10 m. 
IL-6
0
 
 triggers a Notch-3/CA-IX dependent increase in the invasiveness of MS and MCF-7 cells. 
The results illustrated in Figure 5B pointed out that IL-6 induces a Notch-3/ERK mediated 
up-regulation of CA-IX expression in absence of hypoxia. We then investigated the activity of the 
IL-6/Notch-3/CA-IX axis in normoxic conditions. We found that the exposure to IL-6 (10ng/ml) 
enhanced the capacity of MCF-7 cells to invade the extracellular matrix, and that such an increase 
was negligible in shN3/MCF-7 cells, and it was also substantially reduced when CA-IX, but not 
SCR siRNA, was administered to IL-6 exposed MCF-7 cells (Figure 7A). In keeping with these 
observations, we found that the administration of anti-IL-6 (1.5g/ml), or the transfection of an IL-6 
specific siRNA or CA-IX siRNA caused a substantial decrease in the invasive potential of T-MS 
compared to SCR siRNA (Figure 7B). Further, the administration of IL-6 (10ng/ml) enhanced the 
invasive potential of N-MS, being the phenomenon blocked by the co-administration of anti-N3 
(1.5g/ml) or the transfection of CA-IX, but not SCR siRNA (Figure 7C). Parallel to these findings, 
we observed that IL-6 enhanced the activity of the extracellular matrix degrading enzyme MMP-2 
in shCT/MCF-7 cells and in SCR siRNA transfected MCF-7 cells, but not in shN3/MCF-7 cells or 
 53
in CA-IX siRNA transfected ones (Figure 7D). These data suggest that the IL-6/Notch-3 dependent 
up-regulation of CA-IX gene enhances the invasive behaviour of MCF-7 cells and MS. 
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FIGURE 7. IL-6/Notch-3 cross talk enhances the invasive potential of MS and MCF-7 cells by 
means of CA-IX up-regulation. 
A, Boyden invasion chamber assay in MCF-7 cells, in shN3/shCT MCF-7 cells, and in MCF-7 
transiently transfected with SCR/CA-IX siRNA (1g, 72h pre-exposure), in presence/absence of IL-
6 (10ng/ml, 24h), (n=5, *p=0.0001, **p=0.0001, #p=0.0001, anova test), RT-PCR analysis of CA-
IX mRNA in SRC/CA-IX siRNA administered cells is reported in the insert panel; B, Boyden 
chamber invasion assay of day 7 secondary T-MS in presence/absence of anti-IL6 (1.5g/ml, 24h), 
or transfected with IL-6 or CA-IX or SCR siRNA (1g, 72h of pre-exposure, n=3, *p=0.003, 
**p=0.042, §p=0.0001, anova test), RT-PCR analysis of IL-6 and CA-IX mRNA level is reported; 
C, Boyden chamber invasion assay of day 7 secondary N-MS exposed to IL-6 (10ng/ml, 24h) in 
presence/absence of anti-N3 (1.5g/ml, 24h) or SCR/CA-IX siRNA (1g, 72 of pre-exposure) n=3, 
#p=0.036, ##p=0.037, §p=0.0001 anova test). RT-PCR analysis of IL-6, CA-IX and 2 mRNA level 
is reported; D, Zymographic analysis of MMP-2 activity in shN3/shCT MCF-7 cells in 
presence/absence of IL-6 (10ng/ml, 24h), and in MCF-7 cells exposed to IL-6 (10ng/ml, 24h), 
transfected with CA-IX/SCR siRNA (1g, 72 of pre-exposure, n=3 ,*p=0.032, #p=0.025, ##p=0.027, 
anova test, NS=not significant).  
 
Autocrine IL-6 sustains a CA-IX dependent aggressive phenotype in MCF-7-derived, 
hypoxia selected cells (HYPO-7). 
Taken together these results suggest that the establishment of a an autocrine IL-6 loop may 
engender cancer cells with a substantial growth advantage over their normal counterparts. To 
explore this idea we next examined a MCF-7 derived cell population (named HYPO-7), obtained by 
selecting parental MCF-7 cells in the presence of 100M DFX (see Materials and Methods). Such 
cells, cultured for an extensive time period (up to 1 year) in absence of DFX were found to 
constitutively express high levels of IL-6, Notch-3 and CA-IX mRNA (Figure 8A). We found that, 
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compared to SCR siRNA, the administration of IL-6 siRNA to HYPO-7 yielded a decrease in 
Notch-3 and CA-IX mRNA expression, an increase in the susceptibility to DFX induced cell death, 
and a reduction in their invasive potential and MMP-2 activity (Figure 8A). In agreement with the 
data obtained in MCF-7 cells and MS, we found that the administration of CA-IX, but not SCR 
siRNA, to HYPO-7 cells recapitulated the phenotypic changes induced by IL-6 siRNA in HYPO-7 
cells (Figure 8B). Interestingly, the effects elicited by IL-6 siRNA were also observed when HYPO-
7 cells were exposed to anti-IL6 (1.5g/ml for 24h, data not shown). Of particular importance, 
however, was the observation that the administration of anti-IL6 (1.5g/ml, 24h) caused a down-
regulation of IL-6 mRNA in HYPO-7 cells, as well as in MCF-7(S) and in T-MS (Figure 8C). 
These data suggest that autocrine IL-6 production could promote the aggressiveness of breast 
cancer cells.  
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FIGURE 8. Autocrine IL-6 loop sustains a CA-IX-dependent malignant phenotype in 
hypoxia-selected, MCF-7-derived cells. 
A, MCF-7 derived cell population (HYPO-7) in presence of IL-6/SCR siRNA (1g, 48h of pre-
exposure): RT-PCR analysis of IL-6, Notch-3, CA-IX mRNA level, cell death analysis in presence 
of DFX (600M, 48h), Boyden chamber invasion assay (n=5) and Zymographic analysis (n=3) of 
MMP 2 activity (24h, *p=0.042, **p=0.0001, ***p=0.015, anova test); B, HYPO-7 cells in 
presence of CA-IX/SCR siRNA (1g, 48h of pre-exposure): RT-PCR analysis of IL-6, Notch-3, 
CA-IX mRNA level, cell death analysis in presence of DFX (600M, 48h), Boyden chamber 
invasion assay (n=5) and Zymographic analysis (n=3) of MMP-2 activity (24h, #p=0.034, 
##p=0.0001, ###p=0.018, anova test); C, HYPO-7 cells, MCF-7(S) and T-MS exposed to anti-IL6 
(1.5g/ml) for 24h: RT-PCR analysis of IL-6 mRNA level. 2 was assessed as quantitative control 
for RT-PCR analysis 
 
IL-6 induces an autocrine IL-6 loop which triggers a Notch-3 dependent aggressive 
behaviour in MCF-7 cells. 
Prompted by these observations, we reasoned that IL-6 might be regulate the production of  
its own mRNA. Accordingly, we found that administration of IL-6 (10ng/ml) up-regulated IL-6 
mRNA in MCF-7 cells and N-MS (Figure 9A). Furthermore once exposed to IL-6 (10ng/ml for 
24h), MCF-7 cells expressed IL-6 mRNA, even 2 weeks after the withdrawal of IL-6 from the 
medium (Figure 9B), suggesting that IL-6 auto-regulation might perpetuate phenotypic changes 
caused by exposing breast cancer cells to IL-6. Compared to untreated MCF-7 cells, such cells 
{referred to as MCF-7(2wks)} revealed an up-regulation of Notch-3 and CA-IX mRNA levels, 
paralleled by an enhancement in their invasive potential, and by an increase in MMP-2 activity 
(Figure 9B). The gene up-regulation and the increase in invasive behaviour of MCF-7(2wks) was 
abolished by the administration of anti-IL6 (1.5g/ml), indicating that such features were dependent 
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upon an autocrine IL-6 loop (Figure 9C). Notch-3 signalling was also required for this effect, 
because shN3/MCF-7 cells did not show an up-regulation in CA-IX mRNA nor an enhancement of 
invasive potential, which were both observed in shCT/MCF-7 cells two weeks after their exposure 
to IL-6 (Figure 9D). As expected, the enhanced invasive capacity of IL-6 treated shCT/MCF-7 cells 
was reduced by the transfection of CA-IX siRNA, but not SCR siRNA (Figure 9E). These data 
support the argument that an IL-6 autocrine loop could induce a long term enhancement in the 
aggressive features of breast cancer cells, by sustaining an up-regulation of the Notch-3/CA-IX 
axis. 
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FIGURE 9. Autocrine IL-6 loop sustains a Notch-3/CA-IX dependent aggressive phenotype in 
MCF-7 cells. 
A, MCF-7 cells and N-MS exposed to IL-6 (10ng/ml) for 24h: RT-PCR analysis of IL-6 mRNA 
level; B, MCF-7 cells exposed to IL-6 (10ng/ml, 24h) and assessed at various times (1wk, 2wks) 
after the withdrawal of the cytokine: RT-PCR analysis of IL-6, Notch-3, CA-IX mRNA level, 
Boyden Chamber Invasion assay (n=5) and Zymographic analysis (n=3) of MMP-2 activity (24h, 
*p=0.010, #p=0.012, ##p=0.002, anova test, Post Hoc test for multiple comparisons); C, MCF-7 
cells exposed to IL-6 (10ng/ml) for 24h and assessed 2 weeks after cytokine withdrawal MCF-7-
(2wks), in presence/absence of anti-IL6 (1.5g/ml) for 24h: RT-PCR analysis of IL-6, Notch-3, 
CA-IX mRNA level and Boyden Chamber invasion assay (24h, n=5, **p=0.004, anova test, Post 
Hoc test for multiple comparisons); D, RT-PCR analysis of IL-6, CA-IX mRNA level, and WB 
analysis of Notch-3 and -Actin protein level, Boyden Chamber invasion assay (24h) in shN3/shCT 
MCF-7 cells either untreated or exposed to IL-6 for 24h, and assessed 2 weeks after the cytokine 
withdrawal MCF-7-(2wks) (n=5, §p=0.001, anova test, Post Hoc test for multiple comparisons); E, 
Boyden Chamber invasion assay (24h) and RT-PCR analysis of CA-IX mRNA level in MCF-
7(2wks), transfected with CA-IX/SCR siRNA (1g, 48h of pre-exposure, n=5, §§p=0.002, anova 
test). 2 was assessed as quantitative control for RT-PCR analysis. 
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CHAPTER 2 
ABSTRACT 
 
Autocrine and exogenous IL-6 promotes an aggressive behaviour in breast cancer (stem) cells (see 
CHAPTER 1). We here report that, in human ductal breast cancer, the capability to propagate IL-6 
expressing mammospheres correlates with the in vivo aggressiveness. In vivo, IL-6 expressing 
cancer cells are extremely enriched in lymphovascular tumor emboli, that show high levels of the 
cancer stem cell markers CD44, CD133 and of active EGFr. In vitro, IL-6 up-regulates CD44 and 
CD133 expression, via Notch-3. Xenografts from IL-6 over-expressing MCF-7 cells disclose a 
CD44+/CD133+ cancer stem cell phenotype resembling that of basal-like breast carcinomas. These 
data suggest that IL-6 is the functional link between the aggressive and stem cell like phenotype in 
human breast cancer cells.  
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RESULTS 2 
In vivo association between the stem cell phenotype and aggressiveness in breast cancer 
In vitro, invasive ductal breast carcinoma tissues are endowed with an enhanced capability to 
establish cultures of breast cancer stem/progenitor cells, propagated in EGF-supplemented serum 
free media as CD44/CD133+ mammospheres (MS, Figure 10A and Table 3). In keeping with 
previous data (Figure 1B), we observed that, despite that IL-6 expression is negligible in the 
cognate tumor tissues, MS express IL-6 mRNA (Fig. 10B). Then, in a case series of aggressive 
ductal breast carcinoma specimens (Table 3), we observed, independently from the 
presence/absence of the cytokine in the tumor mass, an over-expression of IL-6 protein in 
lymphovascular tumor emboli (Figure 10C). Further, in keeping with a recent report (Xiao et al., 
2008), lymphovascular tumor emboli expressed high level of the cancer stem cell markers CD44, 
CD133 and of active (p)EGFr (Figure 10D). These data convinced us that IL-6 expression 
associates with an aggressive/stem cell-like phenotype in vitro/in vivo. 
 
 
 
 
Figure 10:A, Primary and secondary MS formation efficiency in ductal breast carcinoma tissues 
(Table 3); Monte Carlo2 for trend, *p=0.011; **p=0.001; B, RT-PCR analysis of interleukin 6 
(IL-6) mRNA expression in ductal breast carcinoma-derived MS and in the cognate tumor  tissues 
(T)
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Figure 10: C, Immunohistochemical analysis of IL-6 protein expression in primary tumor mass and 
lymphovascular tumour emboli (Table 4); D, IHC analysis IL-6, pEGFr, CD44 and CD133 protein 
in primary tumor mass and lymphovascular tumour emboli (Table 4) 
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IL-6 expression induces a stem-cell/basal-like phenotype in breast cancer cells 
IL-6 up-regulates two genes that belong to the basal-like breast carcinoma expression profile: 
Jagged-1 and Carbonic Anhydrase IX (see Figure 4-5). The immunohistochemical analysis on IL-6 
expressing MCF-7 xenografts, that were previously shown to have a growth advantage compared to 
parental MCF-7 cells (Sasser et al., 2007), revealed a substantial up-regulation of CD44 and 
CD133 expression, together with that of a basal-like gene profile, characterized by the down-
regulation of Estrogen Receptor alpha (ER) and the up-regulation of EGFr and Cytokeratin 5 
(CK5) expression (Figure 11A). In vitro, the transfection with IL-6 siRNA downregulated the basal-
like gene profile in IL-6 expressing breast cancer cells (Figure 11B). Accordingly, CK5, CA-IX and 
Jagged-1 mRNA expression was decreased in MCF-7(S) exposed to anti-IL6 or generated from 
shN3 infected cells, and CK5 and Jagged-1 expression was down-regulated in MS exposed to anti-
IL6 (Figure 11C).  
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FIGURE 11: A, IHC analysis of CD44, CD133, Cytokeratin 5 (CK5), Carbonic Anhydrase IX 
(CA-IX), EGFr and estrogen receptor (ER) expression in xenografts established from MCF-7 cells 
stably transfected with empty  vector (CTR) or IL-6 encoding vector (Sasser et al., 2007); B, RT-
PCR analysis of CD44, CD133, CK5, CA-IX, Jagged-1, EGFr and IL-6 mRNA in MDA-MB-157 
(p53 null), 231 (p53 Codon mutation 280) and 468 (p53 Codon mutation 273), transiently 
transfected with SCR/IL-6 siRNA (1g, 72h); C, RT-PCR analysis of CK5, CA-IX, Jagged-1 in 
MCF-7(S) administered with anti-IL6 (1.5g/ml, 24h) and in shCT/N3 MCF-7-derived spheroids 
(MCF-7(S)) and RT-PCR analysis of CK5 and Jagged-1 in MS exposed to IL-6 (10ng/ml, 24h), in 
presence of anti-IL6 (1.5g/ml, 24h). 
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CHAPTER 3 
DISCUSSION (CHAPTER 1) 
The first part of this thesis was prompted by the remarkably consistent finding that high IL-6 
serum levels in breast cancer patients are associated with poor outcome, and by the accumulating 
evidence suggesting that IL-6 exerts a direct role in the up-regulation of malignant features in breast 
cancer cells. Herein we have investigated the physiological effects and regulation of IL-6 in MS, 
which can be considered a suitable in vitro model for normal and tumour stem/progenitor cells of 
the mammary gland. 
In regard to the stem cell phenotype of MS, we here show that MS express a variety of genes 
which are up-regulated in normal and cancer stem cell from various tissues, such as Bmi-1 (Liu  et 
al., 2006; Prince et al., 2007), CD44 (Al-Hajj et al., 2003; Li et al., 2007), Oct-4 (Ponti et al., 
2005), BCRP-I (Ho et al., 2007), CD133 (O'Brien et al., 2007). In particular, normal and tumor-
MS are almost entirely composed of CD44+/CD24- cells (the so called breast cancer stem cell 
phenotype, Ponti et al., 2005; Al-Hajj et al., 2003; Liu  et al., 2007), and by a sub-population of 
cells (different in normal and tumor mammospheres from 10 to 20%) expressing CD133 protein. 
Moreover, normal and tumor MS express CK-5 gene which characterizes the basal cell 
compartment in which stem/progenitor cells of the mammary gland are harboured in vivo (Boecker 
and Buerger, 2003). In this regard, recent data suggest CK-5/CD44+, Bmi-1 expressing cells 
represent cancer stem cells of head and neck squamous carcinoma (Prince et al., 2007). Overall, 
the available data support the notion that MS are substantially enriched in stem/progenitor cells, 
compared to the tissues they have been obtained from. 
We provide evidence that T-MS obtained from node invasive tumours express higher IL-6 
mRNA levels than MS obtained from normal tissue of the same patients. Conversely, no difference 
was found when MS from scarcely invasive tumours are examined. We also find  that IL-6 mRNA 
levels are readily detected ex vivo only in CK-5 positive basal-like breast carcinoma tissues an 
uncommon form of biological aggressive breast carcinoma with stem cell-like features, including 
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high levels of CD133 and CD44 expression (Nielsen et al., 2004; Bertucci et al., 2007). We also 
show that these tumours express high levels of the stem cell regulatory gene Bmi-1, which was 
recently shown to be expressed at high levels in T-MS compared to their differentiated epithelial 
progeny (Liu  et al., 2006). In addition Bmi-1 is also up-regulated in CD44+/CD24- breast cancer 
cells (Liu  et al., 2006), and it is highly expressed in a CK-5/CD44+ positive sub-population of 
putative head and neck squamous carcinoma cancer stem cells (Prince et al., 2007). We also 
document that like basal-like carcinoma cells, T-MS also express the CK-5/14, EGF-R, CD133, 
Bmi-1 and IL-6 genes. Thus T-MS derived from ductal breast carcinoma would appear to possess at 
least some of the stem cell-like characteristics of basal-like breast carcinoma. Our findings on basal 
like breast carcinomas support the hypothesis that IL-6 gene expression is related to breast cancer 
stem cell phenotype. Accordingly, it has been shown that IL-6 gene expression is high in breast 
cancer cell lines enriched in CD44+/CD24- invasive cells (Sheridan et al., 2006). Moreover, IL-6 
gene expression shows up in MCF-7 derived spheroids (this thesis), which have been shown to 
contain a high proportion of CD44+/CD24- cells (Phillips et al., 2006). Overall, these data support 
the existence of a tight relationship between cancer stem cells and IL-6 expression. 
Moreover, we also provide evidence that the effects of IL-6 on on MS require a functional 
Notch-3 signalling pathway. Notch-3, a member of the stem cell regulatory Notch family that 
governs stem cell homeostasis and turnover throughout species, modulates morphogenetic 
processes in the mammary gland; and when hyper-expressed in transgenic mice, Notch-3 also 
promotes mammary gland carcinogenesis (Hu et al., 2006). Interestingly, the Notch-3-dependent 
activation of the ERK pathway has been reported in both lung cancer and lymphoma cell model 
(Haruki et al., 2006; Talora et al., 2003). Here, we show that Notch-3 dependent ERK activation 
in breast cancer via IL-6 targets the activation of Jagged-1, which belongs to a family of Notch 
ligands (Reedijk et al., 2005; Stylianou et al., 2006), and CA-IX, a hypoxia survival gene. 
Importantly, siRNA knock-down experiments reveal that both Notch-3 and Jagged-1 are 
functionally required for spheroid formation and for MS self-renewal. Consequently, our data 
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suggest that IL-6 may trigger a potential autocrine/paracrine Notch-3/Jagged-1 loop to boost 
stem/progenitor self-renewal in the mammary gland. Furthermore, in agreement with previous 
findings (Reedijk et al., 2005; Stylianou et al., 2006; Charafe-Jauffret et al., 2006), we show 
that Jagged-1 gene expression correlates with a basal-like breast carcinoma phenotype. Because the 
IL-6 receptor is expressed at higher levels in basal-like breast carcinomas than in other breast 
cancer subtypes (Nielsen et al., 2004), we hypothesize that the IL-6/Notch-3/Jagged-1 axis may 
confer a growth advantage to basal-like carcinoma cells, and also to ductal breast carcinoma stem 
cells. 
We also show that the CA-IX hypoxia survival gene is up-regulated by IL-6 and also 
sustains the invasive potential of breast cancer cells and MS. CA-IX catalyzes carbonic dioxide 
hydrolysis (Svastova et al., 2004) to facilitate survival under conditions of  hypoxia by increasing 
the concentration of basic equivalents in the cytoplasm, which simultaneously lowers the pH in the 
extracellular space thereby creating a favourable environment for the activation of the extracellular 
matrix degrading enzymes, such as MMP-2 (Rofstad et al., 2006; Duffy et al., 2000). Remarkably, 
a higher MMP-2 expression level has been associated with poor prognosis in breast cancer (Duffy 
et al., 2000). In addition, CA-IX hyper-expression has been associated with reduced survival and 
poor outcome in breast cancer patients (Hussain et al., 2007; Brennan et al., 2006), and it has also 
been found to be over-expressed in basal-like breast carcinomas (Makretsov et al., 2004; Garcia et 
al., 2007). Overall, the up-regulation of CA-IX and  Jagged-1 adds to a growing number of genes, 
(i.e., CK-5, CK-14, EGF-R, CD133, CD44, Bmi-1, IL-6) which also convey a tight similarity 
between T-MS and basal-like breast carcinoma. Finally we present data regarding the autocrine IL-
6 loop in breast cancer cells. In particular, we show that IL-6 up-regulates its own mRNA, thus 
perpetuating the effects of transient IL-6 exposure of breast cancer cells. In addition, this autocrine 
IL-6 loop requires active Notch-3 expression. Hence, our data suggest that the up-regulation of IL-6 
gene expression in response to stress conditions (hypoxia), or to inflammation (IL-6 itself) may be 
maintained by an autocrine mechanism in Notch-3 stem/progenitor cells of the mammary gland. 
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Noteworthy, in this investigation we show that IL-6 triggers self-renewal and the invasive 
capacity of MS obtained from normal mammary tissue. At first glance, this finding could be 
surprising. However, we must consider that the inflammatory response is a physiologic mechanism 
aimed at repairing damaged tissues (Coussens and Werb, 2002). It is therefore conceivable that 
stem/progenitor cells are able to respond to an inflammatory stimulus (such as IL-6), by a process 
which promotes proliferation (and self-renewal) and stimulates the migration towards locations 
whereby tissue repair is required. In this regard, we examined the capacity of MS to generate 3-
dimensional structures, that is to migrate into matrigel and to generate multi-acinar and 
acinar/ductal structures (Petersen et al., 1992). As shown in Supplementary Figure 8, we obtained 
preliminary evidence that such a morphogenic capacity of MS (upper panel), as well as that of cells 
derived from the trypisn dis-gregation of normal MS (lower panel), may be enhanced by IL-6 
administration. Indeed, only in IL-6 administered cultures, we observed features recalling acinar 
structure with an hollow lumen and of ductal branching (arrow and arrowhead, respectively, lower 
panel). These data, together with those reported in a previous investigation (Dontu et al., 2004), 
support the hypothesis that Notch signalling plays a role in mammary gland morphogenesis, and 
therefore suggest that IL-6 may enhance the morphogenic capacity of mammary gland 
stem/progenitor cells. Instead, we observed that CD44/CK-5 expressing T-MS (Supplementary 
Figure 9, left panel) plated on plastic and on matrigel produce cells which lose the expression of 
some stem cell markers (such as Oct-4, CK-5), acquire the expression of CD24, but that cannot 
generate tri-dimensional structures in matrigel (upper right panel), whereas express both luminal 
(CK-18) and myoepithelial (CK-14) markers (lower right panel). This finding support the notion 
that normal and tumor MS (from the same individual) have different functional properties, and that 
these latter are endowed with an aberrant/defective capacity to differentiate (Dontu et al., 2004).  
It may be indeed argued that the normal MS studied in this investigation had been obtained 
from breast cancer patients. However, although a field effect can not be completely excluded, it has 
been recently demonstrated that in the human breast, no detectable changes in gene expression are 
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detected when non-neoplastic tissues from cancer patients are compared to normal samples from 
women without cancer (Finak et al., 2006). Nevertheless, though it is reasonable that IL-6 could 
participate in the homeostatic mechanism of a normal mammary gland, it has long been established 
that chronic inflammation, and the sustained up-regulation of its mediators, is a cancer predisposing 
condition (Coussens and Werb, 2002). In this regard, recent data indicate that inflammatory cells, 
such as macrophages and lymphocytes, promote cancer growth in the mammary gland (Rao et al., 
2006; Lin et al., 2006). Although the role of inflammation in breast cancer has long been criticized, 
recent experimental and epidemiological data indicate that breast cancer growth may be promoted 
by local and distant inflammatory processes (such as those in the gut), in agreement with the 
hypothesis that soluble factors link inflammation to breast cancer (Rao et al., 2007). In regard to 
this issue, it is worth mentioning that IL-6 serum levels increase with age (Bonafe et al., 2001), and 
that aging is a major risk factor for breast cancer (Balducci, 2003). Hence, we speculate that altered 
IL-6 gene expression in dys-regulated mammary gland/stem progenitor cells may be a contributory 
factor linking aging to breast cancer risk.  
In conclusion, the findings indicate that IL-6 is a potent promoter of malignant features in 
Notch-3 expressing normal and tumor stem/progenitor cells of the mammary gland
DISCUSSION 2 (CHAPTER2) 
The second part of the thesis (CHAPTER 2) was inspired by two observations regarding the 
association between the stem cell phenotype and the aggressive behaviour in breast cancer. The 
first, showing that the capability of generating IL-6 expressing MS increases with the extent of 
lymph node invasion in ductal breast carcinoma. The second, indicating that IL-6 expression in 
breast cancer tissues is several folds up-regulated in lymphovascular tumor emboli, that are MS-like 
structures expressing a CD133/CD44+ stem cell phenotype (Xiao et al., 2008). Thus, we reasoned 
that IL-6 could play a role in the regulation of the aggressive/stem cell phenotype in breast cancer 
cells. According to this hypothesis, we here show that IL-6 up-regulates aggressive features in 
breast cancer cells, together with the expression of CD44, the hallmark of breast cancer stem cells. 
IL-6 also up-regulates CD133, a cancer stem cell marker that is over-expressed in MS, basal-like 
tumors and lymphovascular emboli and that has been recently linked to the breast cancer stem cell 
phenotype. Similarly, xenografts from IL-6 over-expressing breast cancer cells, that have been 
found to grow at a higher extent compared to controls (Sasser et al., 2007), show an up-regulation 
of CD44 and CD133. These data confirm the hypothesis that IL-6 promotes an aggressive/stem cell 
phenotype in breast cancer cells, suggesting that the over-expression of the cytokine and the setup 
of an autocrine IL-6 loop may be of functional relevance for the phenotype of breast cancer 
initiating cells. Intriguingly, we observed that IL-6 expression in breast cancer tissues is also 
increased in rare breast cancer cells or cell clusters that invade the surrounding of the tumor mass. 
These data suggest that the association between the stem cell and the migrating/metastatic 
phenotype, conceptualized as the “migrating cancer stem cell hypothesis” (Brabletz et al., 2005), in 
vivo, may be identified in the breast by the expression of IL-6. 
Both CD44 and CD133 expression has been associated with cancer stem cells and the 
aggressive behaviour, but their functional role is still unknown (Al-Hajj et al., 2003; O’Brien et 
al., 2007). We here report that CD133, but not CD44, exerts a functional impact on the IL-6 to 
promote MS formation. In the first part of the thesis we have shown that IL-6 is expressed in basal-
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like tissues and breast cell lines. In the second part of the thesis, we show that the expression of the 
cytokine promotes the onset of a basal-like phenotype in vitro and in xenografts. The basal-like 
phenotype includes the expression of IL-6/Notch-3 regulated genes, such as Jagged-1 and CA-IX, 
that have been associated with hypoxia survival and aggressiveness of MS (CHAPTER 1). 
Intriguingly, CA-IX expression has been also found in lymphovascular tumor emboli (Colpaert et 
al., 2003). In conclusion, our study provides important insights into the crucial role of 
exogenous/autocrine IL-6 in driving a Notch-3 interplay that promotes aggressiveness in breast 
cancer cells, and pinpoints a biological function for CD133 and CD44 in some aspects of the breast 
cancer stem cell phenotype. Thus, the reported evidence makes it conceivable that the 
pharmacological inhibition of IL-6 driven molecular machinery, that can be achieved by a variety 
molecules that are already in pre-clinical/clinical studies, could be a strategy to counteract the 
aggressiveness of breast cancer, particularly of those subtypes (the inflammatory and basal-like), in 
which the IL-6 dependent cancer stem cell signature is over-expressed. 
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Table 1. Clinical-pathologic parameters of 17 breast ductal carcinomas employed for tumor 
(T-) and normal (N-) mammosphere (MS) generation. 
No
. 
Age (yrs.) pT pN G NG ER 
 
HER-2 EGF-R T-MS N-MS 
1* 55 1 0 2 2 + 0 - Y NA 
2* 82 2 1 2 3 + 0 - Y NA 
3* 61 2 1 2 2 - 2 - Y NA 
4 46 1 1 2 2 + 1 - Y Y 
5 73 2 3 2 2 + 0 - Y Y 
6 62 1 3 3 3 + 2 - Y Y 
7 58 1 0 3 3 + 1 - Y Y 
8 83 1 3 2 3 + 3 - Y Y 
9 63 2 2 3 3 - 3 - Y Y 
10 55 1 0 3 3 + 3 - N Y 
11 59 1 0 3 3 + 1 - Y Y 
12 44 1 0 1 2 + 0 - Y Y 
13 59 1 1 2 2 + 1 - N Y 
14 39 2 3 2 3 + 1 - Y Y 
15 73 1 1 2 3 + 1 - Y Y 
16 85 2 1 3 3 - 0 - N Y 
17 61 2 1 2 3 + 1 - Y Y 
pT: Tumor size; pN: nodal involment; G: Grading; NG: nuclear grading; ER: Estrogen Receptors; 
HER-2: ErbB-2 receptor; Y=yes; NA= not available; N=no. * mRNA from the tumor tissue was 
available. 
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Table 2. Clinical-pathologic parameters of archival breast (n=16) carcinoma tissues assessed 
by RT-PCR analysis. 
Sample Age 
(yrs.) 
pT pN G NG ER HER-2 CK-5 CK-14 EGFR Histotype Basal-Like 
A 40 2 0 3 3 - 0 + + + IDC Y 
B 55 3 0 3 3 - 0 + + + IDC Y 
C 71 1 1 3 3 - 1 + + + IDC Y 
D 47 4 0 3 3 - 0 + + + IDC Y 
E 78 1 0 3 3 - 1 + + + IDC Y 
F 65 1 0 3 3 - 0 + - + IDC Y 
G 57 2 1 3 3 - 0 - - - IDC N 
H 57 3 1 3 3 - 0 - - - IDC N 
I 42 1 0 2 3 - 0 - - - IDC N 
L 49 1 1 3 3 + 2 - - - IDC N 
M 78 4 3 3 3 + 0 - - - IDC N 
N 64 1 0 2 3 - 0 - - - IDC N 
O 63 2 1 2 3 - 2 - - - IDC N 
P 63 1 1 3 3 + 0 - - - IDC N 
Q 60 1 3 3 3 - 2 - - - IDC N 
R 45 2 0 2 2 - 2 - - - IDC N 
 
CK-5: Cytokeratin-5; CK-14: Cytokeratin-14; IDC: infiltrating-ductal-breast carcinoma. Basal-
like breast carcinomas were diagnosed as CK-5 and/or CK-14+, EGF-R+, ER-, HER-2 
negative/low (0/1) ductal breast carcinomas (Nielsen et al., 2004). 
 77
Table 3. MS forming capacity of ductal breast carcinoma tissues. 
n Age  pT pN G ER P53 ErbB2 EGFr I -MS II-MS 
1 55 1 0 3 1 0 0 0 Y N 
2 82 2 1 2 1 0 0 0 Y N 
3 61 2 0 2 0 0 1 0 Y N 
4 46 1 1 2 1 0 1 0 Y N 
5 73 2 3 2 1 0 0 0 Y Y 
6 62 1 3 3 1 0 2 0 Y Y 
7 58 1 0 3 1 0 1 0 N N 
8 83 1 3 2 1 0 3 0 Y Y 
9 63 2 2 3 0 1 3 1 Y Y 
10 55 1 0 3 1 0 3 0 N N 
11 59 1 0 3 1 0 1 0 Y N 
12 44 1 0 1 1 0 0 0 Y N 
13 59 1 1 2 1 0 1 0 N N 
14 39 2 3 2 1 0 1 0 Y Y 
15 73 1 1 2 1 0 1 0 Y N 
16 85 2 1 3 0 1 0 1 N N 
17 61 2 1 3 1 0 1 0 Y N 
18 55 1 0 1 1 0 0 0 N N 
19 54 2 3 3 1 0 1 0 Y N 
20 69 1 3 3 1 0 0 0 Y Y 
21 85 1 1 1 1 0 1 0 N N 
22 33 2 2 3 1 0 1 0 Y Y 
23 34 1 2 3 0 1 3 2 Y N 
24 79 2 1 2 1 0 1 0 N N 
25 78 2 3 3 1 0 2 0 N N 
26 66 2 0 3 1 1 2 1 N N 
27 79 1 1 3 1 0 2 2 N N 
28 71 1 0 1 1 0 0 0 N N 
29 70 2 0 3 1 0 0 0 N N 
30 66 2 0 3 0 0 3 0 N N 
31 77 1 1 2 1 0 1 0 Y N 
32 81 2 3 3 1 1 1 0 Y Y 
33 51 1 0 2 1 0 0 0 N N 
34 63 2 0 3 0 0 0 2 N N 
35 39 1 2 3 1 1 0 0 N N 
36 73 2 0 2 1 0 2 0 Y N 
37 73 1 1 2 0 0 3 2 N N 
38 38 2 3 3 1 0 0 0 Y N 
39 74 1 0 2 1 0 1 0 N N 
40 70 1 0 2 1 0 0 0 N N 
41 69 1 0 2 1 0 2 0 N N 
42 79 1 3 3 0 0 0 0 N N 
43 61 1 2 3 0 0 1 2 N N 
MS from samples 1-17 have been previously reported (Table 1, paper n2). pT, tumor staging; pN, 
lymph-node invasion; G, tumor grading; ER, estrogen receptor alpha; I-/II-MS, primary and 
secondary MS
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Table 4. Ductal breast carcinoma specimens assessed by IHC /CHAPTER 2).  
 Age pT pN G ER p53 ErbB2 EGFr 
LVE1 71 2 2 1 1 0 0 0 
LVE2 73 1 2 2 1 0 1 0 
LVE3 62 1 3 3 1 0 2 0 
LVE4 47 2 3 3 1 1 0 1 
LVE5 69 1 3 2 1 0 0 0 
LNM1 73 1 1 2 0 1 3 2 
LNM2  40 1 1 3 1 0 1 0 
N01 64 1 0 2 1 0 1 0 
N02 58 1 0 3 1 0 1 0 
N03 61 2 0 2 1 0 1 0 
PC 58 2 1 2 1 0 0 0 
 
LVE, breast cancer tissues wherein lymphovascular emboli were present; LNM, breast cancer 
tissues with axillary’s lymph-node metastasis; N0, breast cancer tissues without lymph-node 
invasion; PC, post neo-adjuvant chemotherapy breast cancer tissue sample; pT, tumor staging; pN, 
lymph-node invasion; G, tumor grading; ER, estrogen receptor alpha. 
 
 
 
 
 
 
 79
 
 
 
 
 
 
 
 
 
SUPPLEMENTARY FIGURES (1-9) 
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Supplementary FIGURE 1:Immunohistochemical analysis and percentage (% +/- SD) of 
positivity  of CD44, CD24, Oct3-4, CK-5 in a tissue sample derived tumor mammospheres (T-MS). 
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Supplementary FIGURE 2: Immunohistochemical analisys and percentage (% +/- SD) of 
positivity  of E-cadherin, cytokeratin-14 (CK-14) and cytokeratin-18 (CK-18) in a tissue derived 
tumor mammospheres (T-MS). 
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Supplementary FIGURE 3: Immunohistochemical analysis and percentage (% +/- SD)  of 
positivity  of CD24, CD44, CK-5, CK-14, CK-18 in a tissue sample derived normal mammospheres 
(N-MS).
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Supplementary FIGURE 4: A, Immunohistochemical analysis and percentage (% +/- SD) of 
positivity  of CD133 in tissue sample derived normal- tumor mammospheres (MS); B, 
Immunohistochemical analysis of CK-5, CK-14, EGF-R in a sample of basal-like breast carcinoma 
and in a ductal breast carcinoma sample (Table 2), and RT-PCR analysis of BMI and CD133 
mRNA in breast carcinoma tissues (Table 2); C,  Immunohistochemical analysis of EGF-R in tissue 
sample derived normal- tumor mammospheres (MS).
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Supplementary FIGURE 5: Day 7 secondary N-MS (sample 4) exposed to 1.5 g/ml -Notch-3 
for 72 hours (number of MS per well, n = 3; *, p =0 .018) and representative phase-contrast picture 
(left panel), vital staining in primary day 14 MS and in 7-day secondary MS exposed to 1.5 g/ml 
-Notch-3 (sample 7, right panel). 
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Supplementary FIGURE 6: MCF-7 cells transfected with 500ng of empty or Notch-3 active 
fragment (pNICD-3)-encoding pCDNA3.1 vector for 24 hours in the presence or absence of 10 
UO126 for 6 hours: RT-PCR analysis of Jagged-1 mRNA level and WB analysis of Notch-3 protein 
level.; MCF-7 cells exposed to 100M DFX for 24 hours, transfected with 1g of N3 or CTR 
shRNA encoding plasmid for 48 hours: WB analysis of Notch-3, pERK, and total ERK protein and 
RT-PCR analysis of Jagged-1 mRNA level. -Actin and 2 mRNA were assessed as quantitative 
CTRs for WB and RT-PCR analysis, respectively. 
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 Supplementary FIGURE 7: Day 7 secondary N-/T-MS (sample 7) treated with 1g of CA-
IX/SCR siRNA in the presence of 100M DFX for 72 hours: vital staining (n =3; *, p= 0.018; #, 
p=0.008), RT-PCR analysis of CA-IX mRNA level. Data are reported as mean +/- SD. 2 mRNA 
was assessed as quantitative control for RT-PCR analysis. 
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Supplementary FIGURE 8: MS were generated from 2 breast cancer patients: Sample n.1 gave 
raise only to MS from the normal tissue, Sample n.2 generated MS from both normal and tumor 
tissues. 3D-assay was performed using Growth Factor Reduced Matrigel (BD Biosciences, 
Frankling Lakes, NJ), which was thawed overnight and kept at 4°C until use. Day 14 normal MS 
from Sample 1 were re-suspended in 150l complete MEGM containing 2% of Matrigel, and 
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layered on the top of 300l pre-solidified Matrigel, in 24 wells plates. IL-6 was added in one culture 
well, to a final concentration of 10ng/ml. Cultures were re-fed every 5 days with 150l of MEGM 
2% Matrigel. Day 14 normal and tumor MS were tryspin dissociated and 2000 cells derived from 
each MS cultures were embedded in 600l of cold Matrigel. 300l of each cell suspension were 
seeded in 24 wells plates. IL-6 was added in one of each culture wells, to a final concentration of 
10ng/ml. Cultures were re-fed every 5 days with 150l of MEGM 2% Matrigel.  
 
 
 
 
 
 
 
 
 
 
 
Supplementary FIGURE 9: T-MS-derived cells plated on plastic: immunofluorescence (FITC), 
nuclear contrast (PI); T-MS-derived cells in 3D culture: Immunohistochemistry (IHC): % of 
positive cells (±SD) is reported. Cells from tumor MS were also allowed to grow on plastic at 
clonogenic density (102 x cm2) and were then fixed in cold Methanol for 5 min for 
Immunofluoresence (IF) analysis.  IHC analysis was performed on Matrigel cultures, re-suspended 
in 2% Agarose Fixed in Paraformaldeide and embedded in Paraffin, as described in Materials and 
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r counterstaining. Primary antibodies used for IHC and IF are described 
in Materials and Methods. 
Methods. For IF, FITC-conjugated antibodies were purchased from Santa Cruz. Propidium Iodide 
(Sigma) was used as nuclea
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